Ledipasvir–sofosbuvir for treating chronic hepatitis C

Technology appraisal guidance
Published: 25 November 2015
www.nice.org.uk/guidance/ta363
Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance are at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.
Contents

1 Guidance ............................................................................................................................................................................ 5
   Table 1 Ledipasvir–sofosbuvir for treating adults with chronic hepatitis C ............................................................ 5

2 The technology ................................................................................................................................................................ 8

3 The company's submission ........................................................................................................................................ 9
   Clinical effectiveness .................................................................................................................................................. 9
   Cost effectiveness ..................................................................................................................................................... 17
   ERG comments on the clinical effectiveness .............................................................................................................. 27
   ERG comments on the cost effectiveness ...................................................................................................................... 29
   Equality .................................................................................................................................................................. 37
   Company's additional evidence .................................................................................................................................. 38
   ERG comments on company's additional evidence ................................................................................................. 41

4 Consideration of the evidence .................................................................................................................................. 43
   Clinical effectiveness ................................................................................................................................................ 45
   Cost effectiveness ..................................................................................................................................................... 50
   Genotypes 1 and 4 .................................................................................................................................................... 54
   Genotype 3 ............................................................................................................................................................. 57
   People co-infected with HIV .................................................................................................................................... 59
   People with advanced liver disease and after liver transplant ...................................................................................... 60
   Innovation ............................................................................................................................................................. 61
   NHS England .......................................................................................................................................................... 61
   Pharmaceutical Price Regulation Scheme ................................................................................................................... 64
   Equality issues ....................................................................................................................................................... 64
   Summary of Appraisal Committee's key conclusions ................................................................................................. 65

5 Implementation ........................................................................................................................................................... 75

6 Review of guidance .................................................................................................................................................... 76

7 Appraisal Committee members, guideline representatives and NICE project team ............................................. 77

© NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).
Appraisal Committee members ................................................................................................................................. 77

Guideline representatives .............................................................................................................................................. 79

NICE project team .......................................................................................................................................................... 79

8 Sources of evidence considered by the Committee ............................................................................................... 81

About this guidance .......................................................................................................................................................... 84
1 Guidance

1.1 Ledipasvir–sofosbuvir is recommended as an option for treating chronic hepatitis C in adults, as specified in table 1.

Table 1 Ledipasvir–sofosbuvir for treating adults with chronic hepatitis C

<table>
<thead>
<tr>
<th>HCV genotype, liver disease stage</th>
<th>Duration (weeks)</th>
<th>Recommendation according to treatment history</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Untreated</td>
<td>Treated</td>
</tr>
<tr>
<td>Ledipasvir–sofosbuvir</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1, without cirrhosis</td>
<td>8</td>
<td>Recommended</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not the licensed regimen for this population</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>Not recommended</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Recommended</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>Not the licensed regimen for this population</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not recommended</td>
</tr>
<tr>
<td>1, with compensated cirrhosis</td>
<td>12</td>
<td>Recommended</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Recommended only if all the following criteria are met:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Child–Pugh class A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• platelet count of 75,000/mm³ or more</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• no features of portal hypertension</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• no history of an HCV-associated decompensation episode</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• not previously treated with an NS5A inhibitor.</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>Not recommended</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not recommended</td>
</tr>
<tr>
<td>4, without cirrhosis</td>
<td>12</td>
<td>Not recommended</td>
</tr>
<tr>
<td>---------------------</td>
<td>----</td>
<td>----------------</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>Not the licensed regimen for this population</td>
</tr>
<tr>
<td>4, with compensated cirrhosis</td>
<td>12</td>
<td>Recommended</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>Not recommended</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Ledipasvir–sofosbuvir plus ribavirin**

<table>
<thead>
<tr>
<th>1</th>
<th>Not the licensed regimen for this population</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Not recommended</td>
</tr>
<tr>
<td>4</td>
<td>Not the licensed regimen for this population</td>
</tr>
</tbody>
</table>

**Abbreviation: HCV, hepatitis C virus.**

**Treated – the person's hepatitis C has not adequately responded to interferon-based treatment.**

1.2 It is recommended that the decision to treat and prescribing decisions are made by multidisciplinary teams in the operational delivery networks put in place by NHS England, to prioritise treatment for people with the highest unmet clinical need.

1.3 People whose treatment with ledipasvir–sofosbuvir is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS
clinician consider it appropriate to stop.
2 The technology

2.1 Ledipasvir–sofosbuvir prevents hepatitis C virus (HCV) replication by inhibiting non-structural protein (NS) 5A (targeted by ledipasvir) and NS5B (targeted by sofosbuvir) proteins. Ledipasvir–sofosbuvir (Harvoni, Gilead Sciences) has a marketing authorisation in the UK for treating chronic hepatitis C in adults. However, the marketing authorisation recommends specific treatment durations for HCV genotypes 1, 3 and 4 only, and states that ledipasvir–sofosbuvir should not be used in people with HCV genotypes 2, 5 and 6. The recommended dose is 1 daily tablet containing a fixed-dose combination of 90 mg ledipasvir and 400 mg sofosbuvir. It is taken orally for 8, 12 or 24 weeks, with or without ribavirin. The recommended treatment duration and whether ribavirin is co-administered depends on genotype, treatment history and presence of cirrhosis. For full details of the recommended treatment durations with or without ribavirin, see table 1 of the summary of product characteristics.

2.2 The summary of product characteristics lists the following 'very common' adverse reactions for ledipasvir–sofosbuvir, with or without ribavirin: fatigue and headache. For full details of adverse reactions and contraindications, see the summary of product characteristics.

2.3 The cost of ledipasvir–sofosbuvir is £12,993.33 per 28-tablet pack (excluding VAT; company’s evidence submission). The cost of a 8-week course of treatment is £25,986.66 and a 12-week course is £38,979.99 (both excluding VAT), not including the cost for ribavirin. The company has agreed a nationally available price reduction for ledipasvir–sofosbuvir with the Commercial Medicines Unit. However, this contract agreement was not presented by the company and therefore it could not be considered in this appraisal. Costs may vary in different settings because of negotiated procurement discounts.
3 The company's submission

The Appraisal Committee (section 7) considered evidence submitted by Gilead Sciences and a review of this submission by the Evidence Review Group (ERG; section 8).

Clinical effectiveness

3.1 The company did a systematic literature review to identify studies evaluating the clinical effectiveness of ledipasvir–sofosbuvir for treating chronic hepatitis C. It presented 10 studies of ledipasvir–sofosbuvir with and without ribavirin in adults whose chronic hepatitis C was either previously untreated or previously treated (described as treatment naive and treatment experienced in the Committee papers). The company focused its clinical effectiveness submission on 3 phase III non-randomised controlled trials in people with HCV genotype 1 (ION-1 [previously untreated], ION-2 [previously treated] and ION-3 [previously untreated]). The other 7 studies submitted by the company were phase II studies and were included as 'supportive evidence'. Of these 7 studies:

- 2 included people with either previously untreated or previously treated genotype 1 HCV (ELECTRON, LONESTAR)
- 1 included people with previously treated genotype 1 HCV (SIRIUS)
- 1 included people with either previously untreated or previously treated genotype 1 or 3 HCV (ELECTRON-2)
- 1 included people with either previously untreated or previously treated genotype 1 or 4 HCV (SYNERGY)
- 1 included people with genotype 1 HCV co-infected with HIV (ERADICATE)
- 1 included people with genotype 1 or 4 HCV with advanced liver disease or after liver transplant (SOLAR-1).

Only the results of studies of durations of ledipasvir–sofosbuvir treatment (with or without ribavirin) that have a marketing authorisation in the UK, and the results of studies included in the company's economic model, are presented here.
Genotype 1: Previously untreated HCV

3.2 ION-1 was an international (99 centres in Europe and the USA; including 7 centres in England), open-label, non-randomised controlled trial of 865 adults with previously untreated genotype 1 HCV. The treatment groups that supported the dosage in the UK marketing authorisation were:

- ledipasvir–sofosbuvir once daily for 12 weeks (n=214)
- ledipasvir–sofosbuvir once daily for 24 weeks (n=217).

Randomisation was stratified by HCV genotype 1 subtype (1a or 1b) and the presence or absence of cirrhosis. The company stated that the baseline patient characteristics were generally balanced among the 4 treatment groups. People were assessed for up to 24 weeks after treatment stopped.

3.3 ION-3 was a multicentre (59 centres in the USA), open-label, non-randomised controlled trial in 647 adults with previously untreated genotype 1 HCV without cirrhosis. The treatment groups that supported the dosage in the UK marketing authorisation were:

- ledipasvir–sofosbuvir for 8 weeks (n=215)
- ledipasvir–sofosbuvir for 12 weeks (n=216).

Randomisation was stratified by HCV genotype 1 subtype (1a or 1b). The company stated that the baseline patient characteristics were generally balanced across the treatment groups. People were assessed for up to 24 weeks after treatment stopped.

3.4 The primary outcome measure of both ION-1 and ION-3 was sustained virological response 12 weeks after stopping treatment (SVR12). A ‘full analysis set’ population was used to analyse the efficacy outcomes for both trials (that is, people who were randomised into the study and had at least 1 dose). The results were compared with an ‘adjusted’ historical control rate of 60% for SVR12 with peginterferon alfa-2a and ribavirin taken from phase III telaprevir (ADVANCE) and boceprevir (SPRINT-2) studies. In both ION-1 and ION-3, each treatment group had an SVR12 superior to the historical control rate of 60% (p<0.001 for all comparisons). The results for the populations of interest are given in table 2. All people who had an SVR12 also had an SVR24 in both trials (that is, all those whose HCV had a sustained virological response 12 weeks after treatment
maintained sustained virological response 24 weeks after treatment).

### Table 2 Sustained virological response rates at 12 weeks for ledipasvir–sofosbuvir in people with HCV genotype 1

<table>
<thead>
<tr>
<th>Patient population</th>
<th>Subgroup</th>
<th>Duration (weeks)</th>
<th>Study</th>
<th>SVR12 % (n/N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 1 HCV without cirrhosis</td>
<td>Previously untreated</td>
<td>8</td>
<td>ION-3</td>
<td>94.0 (202/215)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12</td>
<td>ION-3</td>
<td>96.3 (208/216)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ION-1</td>
<td>99.4 (179/180)</td>
</tr>
<tr>
<td></td>
<td>Previously treated</td>
<td>12</td>
<td>ION-2</td>
<td>95.4 (83/87)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>24</td>
<td>ION-2</td>
<td>98.9 (86/87)</td>
</tr>
<tr>
<td>Genotype 1 HCV with compensated cirrhosis</td>
<td>Previously untreated</td>
<td>12</td>
<td>ION-1</td>
<td>94.1 (32/34)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>24</td>
<td>ION-1</td>
<td>97.0 (32/33)</td>
</tr>
<tr>
<td></td>
<td>Previously treated</td>
<td>12</td>
<td>ION-2</td>
<td>86.4 (19/22)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>24</td>
<td>ION-2</td>
<td>100 (22/22)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SIRIUS</td>
<td>97.4 (75/77)</td>
</tr>
</tbody>
</table>

Abbreviations: HCV, hepatitis C virus; SVR12, sustained virological response at week 12.

Previously treated – the person's hepatitis C has not adequately responded to either peginterferon alfa plus ribavirin or peginterferon alfa plus ribavirin plus a protease inhibitor.

3.5 Pre-specified subgroup analyses of ION-1 were done based on patient characteristics and the randomisation strata. The company stated that high SVR12 rates were seen in people with characteristics historically associated with poor response including: cirrhosis, genotype 1a (which is considered harder to treat than 1b), a single nucleotide polymorphism without 2 copies of the C allele near their IL28B gene (that is, non-CC genotype IL28B polymorphism), and in specific ethnic groups.

3.6 Pre-specified subgroup analyses of ION-3 were based on patient characteristics...
and the randomisation strata. The SVR12 rates in people who had ledipasvir–sofosbuvir for 8 weeks ranged from 89% to 100% in all subgroups. The company commented that the SVR12 rates in pre-specified subgroups, including those historically associated with poor response to interferon treatment, were similar to those seen in the overall population, across the treatment groups. The company also did a post-hoc analysis of relapse rates associated with baseline HCV ribonucleic acid (RNA). This analysis showed that:

- **For people with baseline HCV RNA of less than 6 million international units (IU)/ml** (viral load, or the number of virus particles in the blood; a viral load less than 6 million IU/ml has been linked to better response to treatment) relapse rates were similar between the 8-week (2 of 121 people; 2%) and 12-week (2 of 128 people; 2%) ledipasvir–sofosbuvir treatment groups.

- **For people with baseline HCV RNA of 6 million IU/ml or more**, the relapse rates were different between the 8-week (9 of 92 people; 10%) and 12-week (1 of 82 people; 1%) ledipasvir–sofosbuvir treatment groups.

The company concluded that these data supported the use of 8 weeks' ledipasvir–sofosbuvir in people with previously untreated genotype 1 HCV without cirrhosis and a baseline viral load of less than 6 million IU/ml.

**Genotype 1: Previously treated HCV**

ION-2 was a multicentre (64 centres in USA), open-label phase III non-randomised controlled trial in 440 adults with previously treated genotype 1 HCV. The treatment arms that supported the dosage in the UK marketing authorisation were:

- ledipasvir–sofosbuvir for 12 weeks (n=109)

- ledipasvir–sofosbuvir for 24 weeks (n=109).

Randomisation was stratified by HCV genotype 1 subtype (1a or 1b), the presence or absence of cirrhosis, and response to previous treatment (relapse or virological breakthrough compared with no response). The company stated that the baseline patient characteristics were generally balanced across the treatment groups, but there were differences in age between treatment groups (p=0.02). People were assessed for up to 24 weeks after treatment stopped.
The primary outcome measure of ION-2 was SVR12. A ‘full analysis set’ population was used to analyse the efficacy outcomes. The results were compared with an ‘adjusted’ historical control rate of 25% for SVR12 in a population with previously treated HCV, based on data from phase III telaprevir (REALIZE) and boceprevir (RESPOND-2) studies. Each treatment group had a higher SVR12 than the historical rate of 25% (p<0.001 for all comparisons). The results for the populations of interest are presented in table 2. All people who had an SVR12 also had an SVR24.

Pre-specified subgroup analyses were done based on patient characteristics and the randomisation strata. The company stated that high SVR12 rates were seen independent of HCV genotype 1 subtype, previous treatment option and response to previous treatment. The company highlighted that in people with cirrhosis there was a difference (p=0.007) in SVR12 between the 12-week (82–86%) and 24-week (100%) treatments (of note, both of these treatment durations are specified in the marketing authorisation). However, the company stated that this observation should be considered preliminary because ION-2 was not powered for intergroup comparisons. For people previously treated with peginterferon alfa plus ribavirin, SVR12 was between 93% and 100%. For people previously treated with a protease inhibitor plus peginterferon alfa and ribavirin, the SVR12 was between 93.9% and 98%.

Genotype 3

ELECTRON-2 is an ongoing, multicentre (2 centres in New Zealand), open-label, non-randomised controlled trial in adults with genotypes 1, 3 or 6 HCV. It included the following treatment groups, relevant to this appraisal:

- People with previously untreated genotype 3 HCV (with or without cirrhosis) who had ledipasvir–sofosbuvir plus ribavirin for 12 weeks (n=26).
- People with previously treated genotype 3 HCV (with or without cirrhosis) who had ledipasvir–sofosbuvir plus ribavirin for 12 weeks (n=50).

The primary outcome was SVR12. However, at the time of evidence submission the company only had data from an interim analysis for the population with previously treated genotype 3 HCV that reported SVR4. A ‘full analysis set’ population was used to analyse the efficacy outcomes. No statistical hypothesis testing was done. The results for each population are presented in table 3.
Table 3 Sustained virological response rates for 12 weeks’ ledipasvir–sofosbuvir plus ribavirin in people with genotype 3 HCV in ELECTRON-2

<table>
<thead>
<tr>
<th>Patient population</th>
<th>Subgroup</th>
<th>SVR % (n/N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 3 HCV without cirrhosis</td>
<td>Previously untreated</td>
<td>SVR12: 100 (21/21)</td>
</tr>
<tr>
<td></td>
<td>Previously treated</td>
<td>SVR4: 89 (25/28) ¹</td>
</tr>
<tr>
<td>Genotype 3 HCV with compensated cirrhosis</td>
<td>Previously untreated</td>
<td>SVR12: 100 (5/5)</td>
</tr>
<tr>
<td></td>
<td>Previously treated</td>
<td>SVR4: 77 (17/22) ¹</td>
</tr>
</tbody>
</table>

Abbreviations: HCV, hepatitis C virus; SVR, sustained virological response.

Previously treated – the person's hepatitis C has not adequately responded to interferon-based treatment.

¹ The company's response to clarification presented SVR12 data for people with previously treated HCV genotype 3 (82%; 41/50), but did not present the SVR12 data by cirrhosis status.

3.11 Ledipasvir–sofosbuvir with or without ribavirin for 24 weeks was not studied in ELECTRON-2. However, because of the limited clinical data available for the genotype 3 HCV population, ledipasvir–sofosbuvir's marketing authorisation recommends that 24 weeks of therapy (combined with ribavirin) is advised in 'all patients with treatment-experienced [previously treated] HCV genotype 3' and 'those patients with treatment-naive [previously untreated] HCV genotype 3 with cirrhosis', to be conservative. No recommendations about treatment duration and the use of ribavirin are presented in the ledipasvir–sofosbuvir summary of product characteristics for previously untreated genotype 3 HCV in people without cirrhosis, but the company has included this population in its economic model (assuming a 12-week treatment duration).

Genotype 4

3.12 The company stated that only limited data are currently available in people with genotype 4 HCV, from 2 studies:

- ION-1, 2 people with genotype 4 HCV were enrolled; 1 had ledipasvir–sofosbuvir for 12 weeks and 1 had ledipasvir–sofosbuvir plus ribavirin for 24 weeks. Both people had an SVR12.
SYNERGY, a multicentre, open-label phase II non-randomised controlled trial evaluating ledipasvir–sofosbuvir for 12 weeks in adults with genotypes 1 or 4 HCV. Interim SVR data from SYNERGY were available for 14 people. All 14 people had an SVR12.

The company stated that genotype 1 and 4 HCV infections respond to HCV treatments similarly. Therefore, it was recommended in the ledipasvir–sofosbuvir summary of product characteristics that these genotypes are treated similarly.

People with advanced liver disease and after liver transplant

SOLAR-1 is an ongoing multicentre (30 centres in the USA), open-label, phase II, non-randomised controlled trial in adults with genotypes 1 or 4 HCV, and either advanced liver disease or who have had a liver transplant. People were randomised to have ledipasvir–sofosbuvir plus ribavirin for 12 weeks or ledipasvir–sofosbuvir plus ribavirin for 24 weeks. For people before liver transplant with decompensated cirrhosis, interim SVR4 rates were between 90% (Child–Pugh class C; 19 out of 21 people) and 92% (Child–Pugh class B; 24 out of 26 people) for 24 weeks' ledipasvir–sofosbuvir plus ribavirin. For 24 people after liver transplant without decompensated cirrhosis, the interim SVR4 rate was 100% for 24 weeks' ledipasvir–sofosbuvir plus ribavirin. For people after liver transplant with decompensated cirrhosis, interim SVR4 rates were between 50% (Child–Pugh class C; 1 out of 2 people) and 81% (Child–Pugh class B; 13 out of 16 people) for 24 weeks' ledipasvir–sofosbuvir plus ribavirin.

People co-infected with HIV

ERADICATE is an ongoing US single-centre, open-label, phase II, study in adults with previously untreated genotype 1 HCV co-infected with HIV and without cirrhosis. People were allocated to 2 treatment groups of ledipasvir–sofosbuvir for 12 weeks based on whether or not they had received antiretroviral therapy for their HIV. SVR12 was reported in 49 of 50 people (98%, 95% confidence interval [CI] not reported). For people who had not taken antiretroviral therapy before, SVR12 was reported in 13 out of 13 people (100%, 95% CI 75 to 100%). For people who had taken antiretroviral therapy before, SVR12 was reported in 36 out of 37 people (97%, 95% CI 89 to 100%).
Health-related quality of life

3.15 Four health-related quality-of-life questionnaires were used in ION-1, ION-2 and ION-3: Short Form 36 Health Survey (SF-36), Chronic Liver Disease Questionnaire (CLDQ-HCV), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and the Work Productivity and Activity Impairment Questionnaire (WPAI). The company considered that the responses to these 4 questionnaires suggested that ledipasvir–sofosbuvir alone does not generally worsen a person's health-related quality of life between baseline and end of treatment, but a person's health-related quality of life reduces with addition of ribavirin. The company considered that the mean responses of these 4 questionnaires generally improved from the end of treatment to 12 weeks after treatment.

Adverse events

3.16 The company presented data on adverse events from ION-1, ION-2 and ION-3. Across all the treatment groups in these studies, at least 67% of people had at least 1 adverse event. Higher rates were generally seen in treatment groups of longer duration and those including ribavirin. The most common adverse events in people having ledipasvir–sofosbuvir (with or without ribavirin) were fatigue, headache, insomnia and nausea. However, people taking ledipasvir–sofosbuvir with ribavirin had higher rates of adverse events known to be associated with ribavirin therapy, compared with people taking ledipasvir–sofosbuvir without ribavirin. These included anaemia, cough, fatigue, headache, insomnia, irritability, nausea, pruritus and rash. Most adverse events were mild to moderate in severity. Ten of 865 people in ION-1 stopped treatment because of adverse events (all 10 people had an SVR12). No one in ION-2, and 3 of 647 people in ION-3 (the number of these who had an SVR12 was not reported by the company) stopped treatment because of adverse events. No deaths were reported in the studies.

Meta-analysis and mixed treatment comparison

3.17 The company did not do a meta-analysis of the available clinical studies.

3.18 The company did not do a mixed treatment comparison to compare the relative effectiveness of ledipasvir–sofosbuvir with the comparators listed in the scope of the appraisal. It stated that it was not possible because the evidence for
ledipasvir–sofosbuvir came from studies evaluating different treatment durations and without control groups. Therefore it could not identify a common comparator that would allow it to create a network. The company commented that whereas the lack of a mixed treatment comparison may be considered a limitation:

- SVR is a hard and objective end point consistently measured across all studies, and is not subject to bias from the patient or investigator.
- The baseline characteristics of the study populations were similar except for a higher proportion of people with cirrhosis and HCV genotype 1 subtype 1a in the ledipasvir–sofosbuvir studies, both of which the company considered to be historically associated with numerically lower SVR rates.

**Cost effectiveness**

3.19 The company submitted a Markov state-transition model that reflected the natural history of chronic hepatitis C. It compared ledipasvir–sofosbuvir (with or without ribavirin) with the comparators defined in the final scope of the appraisal. The company’s economic model had 9 states, according to disease stage and treatment response. The same model structure was used for all people irrespective of HCV genotype or treatment experience. The company used a monthly cycle length for the first 18 cycles, then 3-monthly until year 2 and yearly thereafter. The company did the economic analysis from an NHS and personal social services perspective and chose a lifetime time horizon (from age 40 [for previously untreated HCV] or 45 [for previously treated HCV] until people reached 100 years). Costs and health effects were discounted at an annual rate of 3.5% and a half-cycle correction was applied from year 3.

3.20 The cost effectiveness of ledipasvir–sofosbuvir was assessed in populations defined by HCV genotype, which included those with cirrhosis:

- previously untreated genotype 1 HCV
- previously untreated genotype 4 HCV
- previously treated genotype 1 or 4 HCV
- previously untreated genotype 3 HCV
• previously treated genotype 3 HCV, unsuitable for interferon therapy.

The company did not include people with previously treated genotype 3 HCV that was suitable for interferon therapy because it considered that it was unlikely that 24-week ledipasvir–sofosbuvir would be cost effective compared with 12-week sofosbuvir plus peginterferon alfa and ribavirin (given the higher treatment costs with ledipasvir–sofosbuvir and no evidence of additional efficacy).

3.21 The company used patient characteristics from the HCV Research UK database to inform the mean age, the proportion with cirrhosis, and weight of the population entering the model. People entered the model in either the non-cirrhotic or compensated cirrhosis stages of disease. People who started treatment in the non-cirrhotic state and were cured would not become symptomatic again. However, people with cirrhosis whose HCV was cured were still at risk of progression to the decompensated cirrhosis and hepatocellular carcinoma state. Those who did not clear the virus after treatment remained in their respective health states, or progressed to more severe stages of chronic HCV. All people in the decompensated cirrhosis health state were assumed to be candidates for liver transplant. The company chose transition probabilities for disease progression from several publications used in recent NICE technology appraisals of treatments for HCV (Cardoso et al. 2010; Fattovich et al. 1997; Grishchenko et al. 2009; Hartwell et al. 2011; Shepherd et al. 2007; Siebert et al. 2005; Thompson et al. 2008). Transition probabilities from the non-cirrhotic to cirrhotic health state varied according to age and genotype according to published literature. Age- and sex-specific general population mortality was also applied to each health state in the company’s model.

3.22 Treatment-effect data for ledipasvir–sofosbuvir were based on SVR12 from the relevant ION studies and ELECTRON-2 (except for the previously treated genotype 3 HCV population for whom only SVR4 data were available). Treatment-effect data for the comparators were taken from publications or the summary of product characteristics. Because there was no mixed treatment comparison (see section 3.18), the estimates of the relative effectiveness of ledipasvir–sofosbuvir with the comparators were based on naive indirect comparisons. In its base-case analysis the company used the ledipasvir–sofosbuvir data from the genotype 1 HCV population for the analysis of the genotype 4 HCV population because:

• the data available for ledipasvir–sofosbuvir in genotype 4 HCV were limited
• the ledipasvir–sofosbuvir summary of product characteristics states that genotype 1 and 4 HCV infections are generally treated in the same way.

The company commented that the cost-effectiveness analysis for the previously treated HCV population considered genotypes 1 and 4 HCV together. However, for the previously untreated HCV population, 8 weeks of ledipasvir–sofosbuvir is only recommended for previously untreated genotype 1 HCV without cirrhosis (people with genotype 4 HCV are treated with 12 weeks of ledipasvir–sofosbuvir only). Therefore, separate analyses were done for previously untreated genotypes 1 and 4 HCV in this population. The company explored genotype 4 data in a scenario analysis. If more than 1 treatment duration was recommended for a given genotype in the ledipasvir–sofosbuvir summary of product characteristics (based on certain patient or clinical characteristics), the company used a weighted average of the efficacy and treatment duration data in the cost-effectiveness analysis (rather than presenting the results for each treatment duration of ledipasvir–sofosbuvir separately; also referred to as a 'blended comparison').

3.23 Resource use and costs in the company's economic model included those for treatment (drug and administration), monitoring during treatment, adverse events and for each health state (that is, monitoring of people after treatment has stopped). Drug costs were based on the list prices in the 'British national formulary' (BNF; August 2014). Monitoring costs were based on NHS reference costs, published literature or the company's clinical expert opinion (if a published source was unavailable). An additional cost for an 'initial patient evaluation' was included for people with previously untreated HCV, but the monitoring requirements for people having interferon-containing treatments or interferon-free treatments did not differ. Treatment durations were also used to estimate drug and monitoring costs, and the proportion of people on a given ledipasvir–sofosbuvir treatment duration was generally based on the company's clinical expert opinion. Costs for each of the health states in the company's economic model were taken from the published literature (Grishchenko et al. 2009; Longworth et al. 2014; Wright et al. 2006) and inflated to 2012–13 prices. Adverse event costs were taken from the BNF and NHS reference costs. The company assumed that the cost of each adverse event also depends on whether the event is actively treated in an outpatient setting, by a hospital registrar or specialist.

3.24 To estimate the health-related quality of life, the company used EQ-5D utility values from Wright et al. (2006) that were based on a UK trial of mild chronic
hepatitis C. For people who had an SVR, the company's economic model included a utility benefit of 0.04 taken from Vera-Llonch et al. (2013). The company's economic model also captured the health-related quality of life of people while on treatment (independent of whether they had cirrhosis or not). The company assumed that the health-related quality of life of people treated with ledipasvir–sofosbuvir without ribavirin did not change while on treatment, but reduced in people having treatments that included ribavirin or interferon. The company stated that these 'on treatment' decrements were assumed to include any effect on health-related quality of life from treatment-related adverse events.

3.25 The company's deterministic cost-effectiveness results for ledipasvir–sofosbuvir compared with the comparators for each population and ordered by cost are given in tables 4–8.

Table 4 Incremental cost-effectiveness results for previously untreated genotype 1 HCV

<table>
<thead>
<tr>
<th>Treatment option</th>
<th>Total</th>
<th>ICER (£/QALY gained)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cost</td>
<td>LY</td>
</tr>
<tr>
<td>No treatment</td>
<td>£18,956</td>
<td>18.30</td>
</tr>
<tr>
<td>PR</td>
<td>£25,308</td>
<td>19.23</td>
</tr>
<tr>
<td>LDV–SOF</td>
<td>£38,713</td>
<td>20.81</td>
</tr>
<tr>
<td>SMV+PR</td>
<td>£38,731</td>
<td>20.14</td>
</tr>
<tr>
<td>TVR+PR</td>
<td>£40,237</td>
<td>19.99</td>
</tr>
<tr>
<td>BOC+PR</td>
<td>£41,299</td>
<td>19.93</td>
</tr>
<tr>
<td>SOF+PR</td>
<td>£45,776</td>
<td>20.54</td>
</tr>
<tr>
<td>SOF+SMV</td>
<td>£65,630</td>
<td>20.74</td>
</tr>
</tbody>
</table>

Abbreviations: BOC, boceprevir; ICER, incremental cost-effectiveness ratio; LDV, ledipasvir; LY, life years; PR, peginterferon alfa + ribavirin; QALY, quality-adjusted life year; SMV, simeprevir; SOF, sofosbuvir; TVR, telaprevir.

Dominated – treatment gives fewer QALYs at greater cost than comparator.
### Table 5 Incremental cost-effectiveness results for previously untreated genotype 4 HCV

<table>
<thead>
<tr>
<th>Treatment option</th>
<th>Total</th>
<th>ICER (£/QALY gained)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cost</td>
<td>LY</td>
</tr>
<tr>
<td>No treatment</td>
<td>£18,956</td>
<td>18.30</td>
</tr>
<tr>
<td>PR</td>
<td>£25,308</td>
<td>19.23</td>
</tr>
<tr>
<td>SMV+PR</td>
<td>£38,731</td>
<td>20.14</td>
</tr>
<tr>
<td>SOF+PR</td>
<td>£45,776</td>
<td>20.54</td>
</tr>
<tr>
<td>LDV–SOF</td>
<td>£46,823</td>
<td>20.81</td>
</tr>
<tr>
<td>SOF+SMV</td>
<td>£65,630</td>
<td>20.74</td>
</tr>
</tbody>
</table>

Abbreviations: ICER, incremental cost-effectiveness ratio; LDV, ledipasvir; LY, life years; PR, peginterferon alfa + ribavirin; QALY, quality-adjusted life year; SMV, simeprevir; SOF, sofosbuvir.

Dominated – treatment gives fewer QALYs at greater cost than comparator.

Extended dominance – a combination of 2 of its comparators provides equal health at a reduced cost.

### Table 6 Incremental cost-effectiveness results for previously treated genotype 1 or 4 HCV

<table>
<thead>
<tr>
<th>Treatment option</th>
<th>Total</th>
<th>ICER (£/QALY gained)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cost</td>
<td>LY</td>
</tr>
<tr>
<td>No treatment</td>
<td>£18,143</td>
<td>17.44</td>
</tr>
<tr>
<td>PR</td>
<td>£24,960</td>
<td>17.83</td>
</tr>
<tr>
<td>TVR+PR¹</td>
<td>£42,101</td>
<td>18.84</td>
</tr>
<tr>
<td>SMV+PR</td>
<td>£43,626</td>
<td>19.17</td>
</tr>
<tr>
<td>BOC+PR¹</td>
<td>£45,897</td>
<td>18.62</td>
</tr>
<tr>
<td>SOF+PR</td>
<td>£46,756</td>
<td>19.16</td>
</tr>
<tr>
<td>LDV–SOF</td>
<td>£49,537</td>
<td>19.58</td>
</tr>
</tbody>
</table>

1. Abbreviation: TVR, telaprevir; PR, peginterferon alfa + ribavirin; SOF, sofosbuvir; BOC, boceprevir.

© NICE 2021. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).
<table>
<thead>
<tr>
<th>Treatment option</th>
<th>Total Cost</th>
<th>Total LY</th>
<th>Total QALY</th>
<th>ICER (£/QALY gained)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With and without cirrhosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PR</td>
<td>£18,937</td>
<td>19.07</td>
<td>14.01</td>
<td>–</td>
</tr>
<tr>
<td>No treatment</td>
<td>£21,509</td>
<td>17.49</td>
<td>12.24</td>
<td>Dominated</td>
</tr>
<tr>
<td>LDV–SOF+RBV</td>
<td>£57,909</td>
<td>20.76</td>
<td>15.48</td>
<td>£26,491</td>
</tr>
<tr>
<td>With cirrhosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOF+PR</td>
<td>£63,419</td>
<td>16.28</td>
<td>9.38</td>
<td>–</td>
</tr>
<tr>
<td>SOF+RBV</td>
<td>£95,947</td>
<td>17.04</td>
<td>9.87</td>
<td>Extended dominance</td>
</tr>
<tr>
<td>LDV–SOF+RBV</td>
<td>£102,645</td>
<td>17.55</td>
<td>10.23</td>
<td>£46,491</td>
</tr>
</tbody>
</table>

Abbreviations: ICER, incremental cost-effectiveness ratio; LDV, ledipasvir; LY, life years; PR, peginterferon alfa + ribavirin; QALY, quality-adjusted life year; RBV, ribavirin; SOF, sofosbuvir.

Dominated – treatment gives fewer QALYs at greater cost than comparator.

Extended dominance – a combination of 2 of its comparators provides equal health at a reduced cost.

TVR and BOC have a UK marketing authorisation for people with HCV genotype 1 only.
Table 8 Incremental cost-effectiveness results for previously treated genotype 3 HCV unsuitable for interferon therapy

<table>
<thead>
<tr>
<th>Treatment option</th>
<th>Total</th>
<th>ICER (£/QALY gained)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cost</td>
<td>LY</td>
</tr>
<tr>
<td>With and without cirrhosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No treatment</td>
<td>£20,614</td>
<td>16.74</td>
</tr>
<tr>
<td>LDV–SOF+RBV</td>
<td>£89,522</td>
<td>19.10</td>
</tr>
<tr>
<td>With cirrhosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOF+RBV</td>
<td>£101,109</td>
<td>14.13</td>
</tr>
<tr>
<td>LDV–SOF+RBV</td>
<td>£105,761</td>
<td>15.24</td>
</tr>
</tbody>
</table>

Abbreviations: ICER, incremental cost-effectiveness ratio; LDV, ledipasvir; LY, life years; QALY, quality-adjusted life year; RBV, ribavirin; SOF, sofosbuvir.

For most comparisons, ledipasvir–sofosbuvir resulted in lower costs 'off treatment' because it was associated with better efficacy (because there was a higher probability of cure, fewer people move to more expensive severe health states). For some comparisons (particularly for previously untreated genotype 1 HCV), ledipasvir–sofosbuvir was also associated with lower 'on treatment' costs because of shorter treatment duration and less intensive monitoring. Across all populations, a higher number of quality-adjusted life years (QALYs) were gained with ledipasvir–sofosbuvir treatment than with the comparators. The company stated that this is because ledipasvir–sofosbuvir is associated with a higher probability of cure and therefore more people enter the SVR health state (associated with improved health-related quality of life) and fewer people progress to the more severe health states (associated with poorer health-related quality of life).

The company presented results of a one-way sensitivity analysis for ledipasvir–sofosbuvir compared with each of the comparators for each population (see section 3.20). The one-way sensitivity analyses showed that the company's incremental cost-effectiveness ratios (ICERs) for ledipasvir–sofosbuvir were most sensitive to changes to the 'on treatment' costs for people without cirrhosis, the discount rates used for costs and
outcomes, the SVR rates of ledipasvir–sofosbuvir and the comparators, and the transition probability from the non-cirrhotic to the compensated cirrhosis health state.

3.28 The company did a scenario analysis using genotype 4 HCV clinical data. For people with previously untreated genotype 4 HCV, the company's ICER comparing ledipasvir–sofosbuvir with no treatment decreased from £10,468 to £9925 per QALY gained, but when using a fully incremental analysis the company's ICER for ledipasvir–sofosbuvir increased from £12,715 (compared with peginterferon alfa plus ribavirin) to £17,390 per QALY gained (compared with simeprevir plus peginterferon alfa and ribavirin). For people with previously treated genotype 4 HCV, the company's ICER comparing ledipasvir–sofosbuvir with no treatment decreased from £13,527 to £12,313 per QALY gained, and when using a fully incremental analysis the company’s ICER for ledipasvir–sofosbuvir decreased from £13,527 (compared with no treatment) to £12,313 per QALY gained (compared with no treatment).

3.29 The company also presented results from probabilistic sensitivity analyses for each population. The probability of ledipasvir–sofosbuvir being cost effective compared with all comparator technologies at £20,000 and £30,000 per QALY gained is given in table 9.

Table 9 Company's probabilistic sensitivity analyses results

<table>
<thead>
<tr>
<th>Population</th>
<th>Probability of being less than £20,000 per QALY gained</th>
<th>Probability of being less than £30,000 per QALY gained</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previously untreated genotype 1 HCV</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Previously untreated genotype 4 HCV</td>
<td>88%</td>
<td>100%</td>
</tr>
<tr>
<td>Previously treated genotype 1 or 4 HCV</td>
<td>88%</td>
<td>100%</td>
</tr>
<tr>
<td>Previously untreated genotype 3 HCV</td>
<td>2.5%</td>
<td>68%</td>
</tr>
<tr>
<td>Previously untreated genotype 3 HCV with compensated cirrhosis</td>
<td>2.1%</td>
<td>8%</td>
</tr>
<tr>
<td>Previously treated genotype 3 HCV, unsuitable for interferon therapy</td>
<td>1.4%</td>
<td>59.8%</td>
</tr>
</tbody>
</table>
Previously treated genotype 3 HCV, unsuitable for interferon therapy, with compensated cirrhosis  

<table>
<thead>
<tr>
<th></th>
<th>78%</th>
<th>83%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbreviations: HCV, hepatitis C virus; QALY, quality-adjusted life year.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3.30 The company presented ICERs for the subgroups of people without cirrhosis and with compensated cirrhosis (see table 10). The company commented that the cost effectiveness may vary in people with cirrhosis because of differences in efficacy and treatment duration of ledipasvir–sofosbuvir or comparator treatments.

**Table 10 Summary of the company's base-case cost-effectiveness results and cost-effectiveness results by cirrhosis status for ledipasvir–sofosbuvir compared with each comparator (£/QALY gained)**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Base case</th>
<th>Non-cirrhotic</th>
<th>Cirrhotic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previously untreated genotype 1 HCV</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOF+PR</td>
<td>Dominant</td>
<td>Dominant</td>
<td>£1349</td>
</tr>
<tr>
<td>SMV+PR</td>
<td>Dominant</td>
<td>Dominant</td>
<td>£3156</td>
</tr>
<tr>
<td>SMV+SOF</td>
<td>Dominant</td>
<td>Dominant</td>
<td></td>
</tr>
<tr>
<td>BOC+PEG-IFN2b+RBV</td>
<td>Dominant</td>
<td>Dominant</td>
<td></td>
</tr>
<tr>
<td>TVR+PEG-IFN2a+RBV</td>
<td>Dominant</td>
<td>Dominant</td>
<td>£1522</td>
</tr>
<tr>
<td>PEG-IFN2a+RBV</td>
<td>£7985</td>
<td>£10,397</td>
<td>£4731</td>
</tr>
<tr>
<td>No treatment</td>
<td>£7458</td>
<td>£8965</td>
<td>£4920</td>
</tr>
<tr>
<td>Previously untreated genotype 4 HCV</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOF+PR</td>
<td>£3869</td>
<td>£6790</td>
<td>£1349</td>
</tr>
<tr>
<td>SMV+PR</td>
<td>£12,399</td>
<td>£23,136</td>
<td>£3156</td>
</tr>
<tr>
<td>SMV+SOF</td>
<td>Dominant</td>
<td>Dominant</td>
<td></td>
</tr>
<tr>
<td>PEG-IFN2a+RBV</td>
<td>£12,715</td>
<td>£18,555</td>
<td>£4731</td>
</tr>
<tr>
<td>Treatment</td>
<td>Previously treated genotype 1 or 4 HCV</td>
<td>Previously untreated genotype 3 HCV (LDV–SOF+RBV)</td>
<td>Previously treated genotype 3 HCV (LDV–SOF+RBV)</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>---------------------------------------</td>
<td>--------------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No treatment</td>
<td><strong>£10,468</strong></td>
<td><strong>£13,734</strong></td>
<td><strong>£4920</strong></td>
</tr>
<tr>
<td><strong>Previously treated genotype</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 or 4 HCV</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOF+PR</td>
<td><strong>£5497</strong></td>
<td><strong>£3011</strong></td>
<td><strong>£11,001</strong></td>
</tr>
<tr>
<td>SMV+PR</td>
<td><strong>£9984</strong></td>
<td><strong>£10,494</strong></td>
<td><strong>£9102</strong></td>
</tr>
<tr>
<td>SMV+SOF</td>
<td>Dominant</td>
<td>Dominant</td>
<td>SW quadrant (^1)</td>
</tr>
<tr>
<td>BOC+PEG-IFN2b+RBV(^2)</td>
<td><strong>£3551</strong></td>
<td><strong>£5748</strong></td>
<td><strong>£1265</strong></td>
</tr>
<tr>
<td>TVR+PEG-IFN2a+RBV(^2)</td>
<td><strong>£9144</strong></td>
<td><strong>£13,741</strong></td>
<td><strong>£4303</strong></td>
</tr>
<tr>
<td>PEG-IFN2a+RBV</td>
<td><strong>£12,491</strong></td>
<td><strong>£16,125</strong></td>
<td><strong>£6666</strong></td>
</tr>
<tr>
<td>No treatment</td>
<td><strong>£13,527</strong></td>
<td><strong>£17,205</strong></td>
<td><strong>£7415</strong></td>
</tr>
<tr>
<td><strong>Previously untreated genotype</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 HCV (LDV–SOF+RBV)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOF+PR</td>
<td><strong>£46,491</strong></td>
<td>NA</td>
<td><strong>£46,491</strong></td>
</tr>
<tr>
<td>SOF+RBV</td>
<td><strong>£19,013</strong></td>
<td>NA</td>
<td><strong>£19,013</strong></td>
</tr>
<tr>
<td>PR</td>
<td><strong>£26,491</strong></td>
<td><strong>£39,149</strong></td>
<td><strong>£17,622</strong></td>
</tr>
<tr>
<td>No treatment</td>
<td><strong>£11,235</strong></td>
<td><strong>£10,549</strong></td>
<td><strong>£12,335</strong></td>
</tr>
<tr>
<td><strong>Previously treated genotype</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 HCV (LDV–SOF+RBV)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOF+RBV</td>
<td><strong>£6210</strong></td>
<td>NA</td>
<td><strong>£6210</strong></td>
</tr>
<tr>
<td>No treatment</td>
<td><strong>£28,048</strong></td>
<td><strong>£33,631</strong></td>
<td><strong>£18,252</strong></td>
</tr>
</tbody>
</table>

Abbreviations: BOC, boceprevir; HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio; LDV, ledipasvir; PEG-IFN, peginterferon alfa; PR, peginterferon alfa + ribavirin; QALY, quality-adjusted life year; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; TVR, telaprevir.

\(^1\) South West (SW) quadrant: ledipasvir–sofosbuvir results in cost savings but fewer QALYs.

\(^2\) TVR and BOC have a UK marketing authorisation for people with genotype 1 HCV only.

Dominant – comparator treatment gives fewer QALYs at greater cost than ledipasvir–sofosbuvir.

Note: The company's ICERs for the subgroup analysis are for ledipasvir–sofosbuvir compared with the reference comparator from the company's base-case incremental analysis. If the company did an incremental analysis for its subgroup analysis, it may indicate alternative comparators.
The company did not present ICERs for the following subgroups included in the final scope of the appraisal.

- **People co-infected with HIV:** The company did not model the co-infected HIV population separately because it considered that the efficacy and safety of ledipasvir–sofosbuvir treatments for people co-infected with HIV and HCV is similar to that seen in people with HCV mono-infection, and as such is treated in the same way. The company stated this approach was validated by its clinical experts and was conservative because HCV–HIV co-infection is likely to progress to severe health states more quickly if left untreated than HCV mono-infection.

- **People who had treatment before and after liver transplant:** The company did not model this subgroup because of a lack of clinical data.

- **Response to previous treatment (for example, null response, partial response, relapse):** The company did not consider this subgroup to be relevant because response to interferon-free treatments (such as ledipasvir–sofosbuvir) is not affected by previous response to interferon-containing treatments.

### ERG comments on the clinical effectiveness

3.32 The ERG considered that it was unlikely that any studies of ledipasvir–sofosbuvir relevant to this appraisal were missed. However, the ERG noted that there were gaps in the reporting of the searches done by the company, and the company’s searches for comparator evidence and adverse events were not systematic.

3.33 The ERG stated that although the 3 phase III studies were open-label, they were generally at low risk of bias. It commented that the phase II studies had small sample sizes but provided data consistent with the phase III trials. The ERG stated, however, that subjective health-related quality-of-life outcomes were subject to bias.

3.34 The ERG noted that historical controls were used because there was no control arm. It commented that there are limitations with using historical controls, particularly when there are changes in the definition of, or diagnostic methods used to detect, the condition under consideration. However, the ERG stated this was unlikely to be an issue for hepatitis C, and that their clinical expert advised that the use of historical controls in this context was considered to be
3.35 The ERG’s clinical experts suggested that the diagnostic criteria used for the disease and the SVR outcomes used in the studies were representative of clinical practice in England. The ERG commented that using SVR12 was appropriate because there is a high correlation between SVR12 and SVR24. However, it noted that SVR4 is not a suitable surrogate end point for cure because there is a chance of relapse between 4 and 12 weeks.

3.36 The ERG highlighted that the results of the company’s subgroup analyses for factors not stratified at randomisation were potentially biased because the respective subgroups may not be well-balanced across treatment arms.

3.37 The ERG commented that ION-1 (people with cirrhosis) and ION-3 could create a network of evidence, although without any links to the comparator treatments. The ERG considered it would have been useful for the company to:

- analyse the 6 treatment arms from these studies and estimate the joint posterior distribution of treatment effect (for example, odds ratios), because it is reasonable to assume that the effectiveness of ledipasvir–sofosbuvir depends on treatment duration

- synthesise the evidence for each comparator (for example, the company acknowledged that a meta-analysis was possible for estimating the SVR rates for boceprevir, peginterferon alfa plus ribavirin, simeprevir and telaprevir in people with genotype 1 HCV).

3.38 The ERG commented that the efficacy of ledipasvir–sofosbuvir does not appear to depend on the patient characteristics pre-specified in the company’s subgroup analyses. However, given that several patient characteristics were pre-specified, it seems reasonable to assume that these characteristics may affect the efficacy of some comparators. The ERG concluded that in a given study, SVR rates for comparator treatments are much more likely to vary compared with SVR rates for ledipasvir–sofosbuvir (that is, using SVR rates from a single comparator study introduces more uncertainty than using SVR rates for ledipasvir–sofosbuvir from a single study).

3.39 The ERG’s clinical experts stated that HCV genotype 1 subtype 1a, baseline viral load and IL28B CC genotype had less effect on response to treatment with ledipasvir–sofosbuvir compared with current treatment options. The ERG’s
clinical experts advised that there was unlikely to be any meaningful differences in baseline characteristics between the populations of the ledipasvir–sofosbuvir and comparator studies that would significantly affect outcomes. The ERG concluded that although baseline characteristics appear similar between intervention and comparator trials, the possibility that other factors differed across trials cannot be ruled out (see section 3.47).

**ERG comments on the cost effectiveness**

3.40 The ERG considered that the company’s model structure was broadly appropriate and in line with previous economic analyses of treatments for hepatitis C.

3.41 The ERG's clinical experts noted that people with genotype 3 HCV and cirrhosis have active treatment because of disease severity. Therefore, it considered that the company's exclusion of 'no treatment' as a comparator for these populations was appropriate.

3.42 The ERG stated that boceprevir and telaprevir do not have a UK marketing authorisation for treating genotype 4 HCV and should not be considered as comparators for this population.

3.43 The ERG commented that it was unclear whether the baseline proportion of people with cirrhosis used in the company’s model reflects the HCV population in England.

3.44 The ERG commented that the details about how transition probabilities from the non-cirrhotic to the compensated cirrhosis health states had been estimated were insufficient for the ERG to critique the robustness of the approach. The ERG highlighted that the transition probabilities from compensated or decompensated cirrhosis to hepatocellular carcinoma were considerably higher for this appraisal (0.0631; Cardoso et al. 2010) than those used by the same company in its economic model for NICE’s technology appraisal guidance on sofosbuvir for treating chronic hepatitis C (0.014; Fattovich et al. 1997).

3.45 The ERG commented that the company's assumption that people cannot die or have disease progression until 12–24 weeks after completing treatment lacks
credibility. However, the ERG acknowledged that the size of bias was likely to be small and would favour treatment options given over longer treatment durations.

3.46 The ERG highlighted that using SVR4 data for the genotype 3 HCV population is likely to overestimate the effectiveness of ledipasvir–sofosbuvir (see sections 3.22 and 3.35).

3.47 The ERG noted that the selection criteria for comparator SVR rates in the company’s economic model were not clear, and that the company’s submission did not indicate the range of SVR estimates possible for the comparators. The ERG stated that because the SVR rates for comparators were estimated from single studies, rather than a meta-analysis of all relevant studies, it was not clear whether they were conservative or optimistic rates. The ERG commented that using naive indirect comparisons breaks randomisation and fails to fully reflect uncertainty around the SVR rates. The ERG concluded that the cost-effectiveness results may be biased by the selection of individual studies and confounded by the effect of other factors such as differences in study design, patient characteristics and trial protocols.

3.48 The ERG stated that the results should be interpreted with caution when using the company’s weighted-average approach (that is, the company included more than 1 treatment duration of ledipasvir–sofosbuvir within its base-case analysis for some populations listed in section 3.20 [for example, previously untreated genotype 1 HCV] and therefore the efficacy and cost inputs used in the model depended on the assumed proportion of people receiving each treatment duration). The ERG also noted that the company’s submission did not explicitly state the treatment durations estimated from the company’s weighted-average approach. The ERG concluded that using cost-effectiveness results dependent on the company’s weighted-average approach may result in the recommendation of some options that represent an inefficient use of NHS resources, particularly when taking into account that there may be clear clinical reasons why specified treatment durations of ledipasvir–sofosbuvir should be considered for specific subgroups of people.

3.49 The ERG highlighted that for people with previously untreated genotype 1 HCV without cirrhosis, the company used a 79% to 21% split between the 8-week and 12-week ledipasvir–sofosbuvir treatments. This was because data from the
HCV Research UK database showed that 79% of this population had a pre-treatment viral load less than 6 million IU/ml (based on the company’s post-hoc subgroup analysis, the company stated this group is likely to have 8 weeks’ treatment; see section 3.6). However, the ERG considered that this criterion is not consistent with the recommendations for this treatment indication in the ledipasvir–sofosbuvir marketing authorisation and is based on a post-hoc analysis of the ION-3 study.

3.50 The ERG considered that the company did not sufficiently explain how choices were made in the selection of costs and utility values used in its economic model, nor did the company specify the source used for resource use estimates.

3.51 The ERG commented that the publication (Vera-Llonch et al. 2013) used by the company to reflect the utility gain associated with achieving SVR was derived using a US EQ-5D tariff of 0.04. It suggested that the utility gain associated with an SVR taken from Wright et al. (2006), which reflects the preferences of the general public in England (that is, using a UK EQ-5D tariff of 0.05) would be more appropriate. The ERG stated that the 'on treatment' decrements used by the company were applied to the entire cycle in the ‘on treatment’ health state rather than for the duration of treatment, but the ERG noted that the effect of this bias was likely to be small.

3.52 The ERG highlighted that health effects on people with HCV (that is, potential for reinfection) and health effects between people (that is, transmission of HCV) were excluded from the company’s model. The ERG explained that:

- Excluding reinfection is likely to overestimate the health benefits of more effective treatments while underestimating their costs (because people may subsequently need retreatment).

- Excluding transmission of HCV may underestimate the health benefits of more effective treatments.

The ERG acknowledged that models used to inform previous NICE technology appraisals of treatments for chronic hepatitis C did not include such health effects and exploring this issue would need a different model structure. However, it concluded that it was concerned that the company’s results were potentially unreliable because the effect on the cost-effectiveness results from these exclusions was unclear.

3.53 The ERG highlighted that the company’s base-case analysis uses point estimates.
of parameters (that is, a deterministic approach) rather than the expectation of
the mean (that is, a probabilistic approach). However, the ERG considered that
the results from the deterministic analyses and probabilistic analyses were
similar in the company's economic model.

3.54 The ERG considered that the results of the company's probabilistic analyses
were limited because of:

- key uncertain parameters (for example, SVR rates) being pre-sampled outside of the
  model rather than sampling from a distribution
- the use of inappropriate distributions for some parameters.

3.55 The ERG presented ICERs for several exploratory analyses, using deterministic
analyses because of the computation time and complexity associated with
running probabilistic analyses. The ERG did the following additional analyses:

- Scenario 1: Developed an ERG-preferred base case exploring each recommended
treatment duration for ledipasvir–sofosbuvir separately (that is, removing the
company's weighted-average approach; see sections 3.22 and 3.48).

- Scenario 2: Explored the alternative recommended treatment durations for
  ledipasvir–sofosbuvir for specific subgroups of people (as stipulated in the marketing
  authorisation for ledipasvir–sofosbuvir).

- Scenario 3: Used alternative transition probabilities based on the sofosbuvir model –
  Fattovich et al. (1997) rather than Cardoso et al. (2010; see section 3.44).

- Scenario 4: Used a UK-valued utility increment derived by Wright et al. (2006; see
  section 3.51).

- Scenario 5: Used shorter time horizons (5 years and 10 years) to test the assumptions
  around exclusion of health effects from reinfection (see section 3.52).

- Scenario 6: An analysis exploring the sensitivity of the ERG's ICERs to changing the
  SVR rates of the comparators used by the company.

Exploratory scenario analyses 3–6 used the ERG-preferred base-case analysis as a
starting point, that is, they all also included scenario 1. The ERG also presented the
results of the ERG's exploratory analyses separately for people with and without
cirrhosis because the ledipasvir–sofosbuvir marketing authorisation makes
recommendations specific to cirrhosis status.
Table 11 Summary of the ERG's incremental cost-effectiveness results for its exploratory analysis of scenario 1 (plus ICERs for scenario 3 in column 5)

<table>
<thead>
<tr>
<th>Previously untreated genotype 1 HCV without cirrhosis</th>
<th>Option</th>
<th>QALYs</th>
<th>Costs</th>
<th>ICER</th>
<th>ICER (scenario 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LDV–SOF 12 weeks</td>
<td>17.20</td>
<td>£42,160</td>
<td>£22,676</td>
<td>£25,526</td>
</tr>
<tr>
<td></td>
<td>SOF+PEG-IFN2a+RBV</td>
<td>17.04</td>
<td>£41,082</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td></td>
<td>SMV+PEG-IFN2a+RBV</td>
<td>16.81</td>
<td>£33,317</td>
<td>£16,601</td>
<td>£18,300</td>
</tr>
<tr>
<td></td>
<td>TVR+PEG-IFN2a+RBV</td>
<td>16.69</td>
<td>£34,631</td>
<td>Dominated</td>
<td>Dominated</td>
</tr>
<tr>
<td></td>
<td>BOC+PEG-IFN2b+RBV</td>
<td>16.41</td>
<td>£35,002</td>
<td>Dominated</td>
<td>Dominated</td>
</tr>
<tr>
<td></td>
<td>PEG-IFN2a+RBV</td>
<td>15.96</td>
<td>£19,205</td>
<td>£6939</td>
<td>£7572</td>
</tr>
<tr>
<td></td>
<td>No treatment</td>
<td>15.07</td>
<td>£13,029</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Previously untreated genotype 1 HCV with cirrhosis</th>
<th>Option</th>
<th>QALYs</th>
<th>Costs</th>
<th>ICER</th>
<th>ICER (scenario 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LDV–SOF 24 weeks</td>
<td>10.08</td>
<td>£101,052</td>
<td>£45,323</td>
<td>£79,899</td>
</tr>
<tr>
<td></td>
<td>SOF+PEG-IFN2a+RBV</td>
<td>9.25</td>
<td>£63,434</td>
<td>£5597</td>
<td>£6597</td>
</tr>
<tr>
<td></td>
<td>SMV+PEG-IFN2a+RBV</td>
<td>8.28</td>
<td>£59,098</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td></td>
<td>BOC+PEG-IFN2b+RBV</td>
<td>8.09</td>
<td>£64,985</td>
<td>Dominated</td>
<td>Dominated</td>
</tr>
<tr>
<td></td>
<td>TVR+PEG-IFN2a+RBV</td>
<td>7.95</td>
<td>£61,326</td>
<td>Extended dominance</td>
<td>Dominated</td>
</tr>
<tr>
<td></td>
<td>PEG-IFN2a+RBV</td>
<td>6.54</td>
<td>£48,266</td>
<td>£5436</td>
<td>£6012</td>
</tr>
<tr>
<td></td>
<td>No treatment</td>
<td>5.25</td>
<td>£41,253</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Previously untreated genotype 4 HCV without cirrhosis</th>
<th>Option</th>
<th>QALYs</th>
<th>Costs</th>
<th>ICER</th>
<th>ICER (scenario 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LDV–SOF 12 weeks</td>
<td>17.20</td>
<td>£42,160</td>
<td>£22,676</td>
<td>£25,526</td>
</tr>
<tr>
<td></td>
<td>SMV+PEG-IFN2a+RBV</td>
<td>16.81</td>
<td>£33,317</td>
<td>£16,601</td>
<td>£18,300</td>
</tr>
<tr>
<td></td>
<td>PEG-IFN2a+RBV</td>
<td>15.96</td>
<td>£19,205</td>
<td>£6939</td>
<td>£7572</td>
</tr>
<tr>
<td>No treatment</td>
<td>15.07</td>
<td>£13,029</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
</tbody>
</table>

**Previously untreated genotype 4 HCV with cirrhosis**

<table>
<thead>
<tr>
<th>Option</th>
<th>QALYs</th>
<th>Costs</th>
<th>ICER</th>
<th>ICER (scenario 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDV-SOF 24 weeks</td>
<td>10.08</td>
<td>£101,052</td>
<td>£45,323</td>
<td>£79,899</td>
</tr>
<tr>
<td>SOF+PEG-IFN2a+RBV</td>
<td>9.25</td>
<td>£63,434</td>
<td>£5597</td>
<td>£6597</td>
</tr>
<tr>
<td>SMV+PEG-IFN2a+RBV</td>
<td>8.28</td>
<td>£59,098</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td>PEG-IFN2a+RBV</td>
<td>6.54</td>
<td>£48,266</td>
<td>£5436</td>
<td>£6012</td>
</tr>
<tr>
<td>No treatment</td>
<td>5.25</td>
<td>£41,253</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

**Previously treated genotype 1 or 4 HCV without cirrhosis**

<table>
<thead>
<tr>
<th>Option</th>
<th>QALYs</th>
<th>Costs</th>
<th>ICER</th>
<th>ICER (scenario 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDV-SOF 12 weeks</td>
<td>16.11</td>
<td>£41,979</td>
<td>£16,566</td>
<td>£18,614</td>
</tr>
<tr>
<td>SOF+PEG-IFN2a+RBV</td>
<td>15.71</td>
<td>£42,387</td>
<td>Dominated</td>
<td>Dominated</td>
</tr>
<tr>
<td>SMV+PEG-IFN2a+RBV</td>
<td>15.67</td>
<td>£38,730</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td>TVR+PEG-IFN2a+RBV</td>
<td>15.62</td>
<td>£36,460</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td>BOC+PEG-IFN2b+RBV</td>
<td>15.48</td>
<td>£39,911</td>
<td>Dominated</td>
<td>Dominated</td>
</tr>
<tr>
<td>PEG-IFN2a+RBV</td>
<td>14.61</td>
<td>£18,984</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td>No treatment</td>
<td>14.31</td>
<td>£12,160</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

**Previously treated genotype 1 or 4 HCV with cirrhosis**

<table>
<thead>
<tr>
<th>Option</th>
<th>QALYs</th>
<th>Costs</th>
<th>ICER</th>
<th>ICER (scenario 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDV-SOF 24 weeks</td>
<td>9.70</td>
<td>£99,222</td>
<td>£32,458</td>
<td>£57,385</td>
</tr>
<tr>
<td>SOF+PEG-IFN2a+RBV</td>
<td>8.59</td>
<td>£63,193</td>
<td>£6630</td>
<td>£8660</td>
</tr>
<tr>
<td>SMV+PEG-IFN2a+RBV</td>
<td>8.31</td>
<td>£62,046</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td>TVR+PEG-IFN2a+RBV</td>
<td>7.46</td>
<td>£63,325</td>
<td>Dominated</td>
<td>Dominated</td>
</tr>
<tr>
<td>BOC+PEG-IFN2b+RBV</td>
<td>6.95</td>
<td>£68,413</td>
<td>Dominated</td>
<td>Dominated</td>
</tr>
<tr>
<td>PEG-IFN2a+RBV</td>
<td>5.74</td>
<td>£47,441</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
</tr>
<tr>
<td>No treatment</td>
<td>5.19</td>
<td>£40,651</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Previously untreated genotype 3 HCV without cirrhosis</td>
<td>Option</td>
<td>QALYs</td>
<td>Costs</td>
<td>ICER</td>
</tr>
<tr>
<td>------------------------------------------------------</td>
<td>------------</td>
<td>-------</td>
<td>----------</td>
<td>-----------</td>
</tr>
<tr>
<td>LDV–SOF+RBV 24 weeks</td>
<td>17.24</td>
<td>£83,331</td>
<td>£88,853</td>
<td>£102,210</td>
</tr>
<tr>
<td>PEG-IFN2a+RBV</td>
<td>16.43</td>
<td>£11,360</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>No treatment</td>
<td>14.57</td>
<td>£14,928</td>
<td>Dominated</td>
<td>Dominated</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Previously untreated genotype 3 HCV with cirrhosis</th>
<th>Option</th>
<th>QALYs</th>
<th>Costs</th>
<th>ICER</th>
<th>ICER (scenario 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDV–SOF+RBV 24 weeks</td>
<td>10.23</td>
<td>£102,645</td>
<td>£46,149</td>
<td>£79,825</td>
<td></td>
</tr>
<tr>
<td>SOF+RBV</td>
<td>9.87</td>
<td>£95,947</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
<td></td>
</tr>
<tr>
<td>SOF+PEG-IFN2a+RBV</td>
<td>9.38</td>
<td>£63,419</td>
<td>£2363</td>
<td>£1392</td>
<td></td>
</tr>
<tr>
<td>No treatment</td>
<td>5.25</td>
<td>£41,253</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Previously treated genotype 3 HCV without cirrhosis, not suitable for interferon therapy</th>
<th>Option</th>
<th>QALYs</th>
<th>Costs</th>
<th>ICER</th>
<th>ICER (scenario 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDV–SOF+RBV 24 weeks</td>
<td>15.97</td>
<td>£84,109</td>
<td>£33,576</td>
<td>£38,834</td>
<td></td>
</tr>
<tr>
<td>No treatment</td>
<td>13.88</td>
<td>£13,936</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Previously treated genotype 3 HCV with cirrhosis, not suitable for interferon therapy</th>
<th>Option</th>
<th>QALYs</th>
<th>Costs</th>
<th>ICER</th>
<th>ICER (scenario 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDV–SOF+RBV 24 weeks</td>
<td>8.76</td>
<td>£105,761</td>
<td>£18,238</td>
<td>£30,495</td>
<td></td>
</tr>
<tr>
<td>SOF+RBV</td>
<td>8.01</td>
<td>£101,109</td>
<td>Extended dominance</td>
<td>Extended dominance</td>
<td></td>
</tr>
<tr>
<td>No treatment</td>
<td>5.19</td>
<td>£40,651</td>
<td>–</td>
<td>–</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BOC, boceprevir; HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; LDV, ledipasvir; LY, life years; PEG-IFN+RBV, peginterferon alfa + ribavirin; SMV, simeprevir; SOF, sofosbuvir; TVR, telaprevir.

Dominated – treatment gives fewer QALYs at greater cost than comparator.
Extended dominance – a combination of 2 of its comparators provides equal health at a reduced cost.

¹ Not applicable for people with genotype 4 HCV.
Table 12 Summary of the ERG’s incremental cost-effectiveness results for its exploratory scenario analysis 2

### Previously untreated genotype 1 HCV without cirrhosis

<table>
<thead>
<tr>
<th>Option</th>
<th>QALYs</th>
<th>Costs</th>
<th>ICER</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDV–SOF 8 weeks</td>
<td>17.12</td>
<td>£29,523</td>
<td>£8894</td>
</tr>
<tr>
<td>SOF+PEG-IFN2a+RBV</td>
<td>17.04</td>
<td>£41,082</td>
<td>Dominated</td>
</tr>
<tr>
<td>SMV+PEG-IFN2a+RBV</td>
<td>16.81</td>
<td>£33,317</td>
<td>Dominated</td>
</tr>
<tr>
<td>TVR+PEG-IFN2a+RBV</td>
<td>16.69</td>
<td>£34,631</td>
<td>Dominated</td>
</tr>
<tr>
<td>BOC+PEG-IFN2b+RBV</td>
<td>16.41</td>
<td>£35,002</td>
<td>Dominated</td>
</tr>
<tr>
<td>PEG-IFN2a+RBV</td>
<td>15.96</td>
<td>£19,205</td>
<td>£6939</td>
</tr>
<tr>
<td>No treatment</td>
<td>15.07</td>
<td>£13,029</td>
<td>–</td>
</tr>
</tbody>
</table>

### Previously untreated genotype 1 HCV with cirrhosis

<table>
<thead>
<tr>
<th>Option</th>
<th>QALYs</th>
<th>Costs</th>
<th>ICER</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDV–SOF 12 weeks</td>
<td>9.94</td>
<td>£62,440</td>
<td>£4518</td>
</tr>
<tr>
<td>SOF+PEG-IFN2a+RBV</td>
<td>9.25</td>
<td>£63,434</td>
<td>Dominated</td>
</tr>
<tr>
<td>SMV+PEG-IFN2a+RBV</td>
<td>8.28</td>
<td>£59,098</td>
<td>Extended dominance</td>
</tr>
<tr>
<td>BOC+PEG-IFN2b+RBV</td>
<td>8.09</td>
<td>£64,985</td>
<td>Dominated</td>
</tr>
<tr>
<td>TVR+PEG-IFN2a+RBV</td>
<td>7.95</td>
<td>£61,326</td>
<td>Extended dominance</td>
</tr>
<tr>
<td>PEG-IFN2a+RBV</td>
<td>6.54</td>
<td>£48,266</td>
<td>Extended dominance</td>
</tr>
<tr>
<td>No treatment</td>
<td>5.25</td>
<td>£41,253</td>
<td>–</td>
</tr>
</tbody>
</table>

### Previously treated genotype 1 or 4 HCV without cirrhosis

<table>
<thead>
<tr>
<th>Option</th>
<th>QALYs</th>
<th>Costs</th>
<th>ICER</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDV–SOF 24 weeks</td>
<td>16.21</td>
<td>£80,577</td>
<td>£77,495</td>
</tr>
<tr>
<td>SOF+PEG-IFN2a+RBV(^1)</td>
<td>15.71</td>
<td>£42,387</td>
<td>Extended dominance</td>
</tr>
<tr>
<td>SMV+PEG-IFN2a+RBV</td>
<td>15.67</td>
<td>£38,730</td>
<td>£45,396</td>
</tr>
<tr>
<td>TVR+PEG-IFN2a+RBV(^1)</td>
<td>15.62</td>
<td>£36,460</td>
<td>£18,550</td>
</tr>
<tr>
<td>Option</td>
<td>QALYs</td>
<td>Costs</td>
<td>ICER</td>
</tr>
<tr>
<td>------------------------------</td>
<td>--------</td>
<td>---------</td>
<td>--------</td>
</tr>
<tr>
<td>LDV–SOF 12 weeks</td>
<td>17.24</td>
<td>£42,997</td>
<td>£39,277</td>
</tr>
<tr>
<td>PEG-IFN2a+RBV</td>
<td>16.43</td>
<td>£11,360</td>
<td>–</td>
</tr>
<tr>
<td>No treatment</td>
<td>14.57</td>
<td>£14,928</td>
<td>Dominated</td>
</tr>
</tbody>
</table>

Abbreviations: BOC, boceprevir; HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio; LDV, ledipasvir; PEG-IFN+RBV, peginterferon alfa + ribavirin; QALY, quality-adjusted life year; SMV, simeprevir; SOF, sofosbuvir; TVR, telaprevir.

Dominated – treatment gives fewer QALYs at greater cost than comparator.

Extended dominance – a combination of 2 of its comparators provides equal health at a reduced cost.

4 Not applicable for people with genotype 4 HCV.

Equality

3.56 The company stated that people with genotype 4 HCV have a particularly high unmet need, and that minority ethnic groups have a higher proportion of people who have genotype 4 HCV than people who have genotypes 1 or 3 HCV in the UK. The company provided NICE with evidence from an HCV genotype surveillance report commissioned by the company to be produced by Public Health England. This shows the proportion of people of white or white British family origin with genotype 1 or 3 HCV as 81% and 72% respectively, whereas minority ethnic groups represent 8% and 18% respectively. The proportion of people with genotype 4 HCV of white or white British family origin is 44%, whereas minority ethnic groups represent 39% (see table 13). Additionally, the company presented commercial-in-confidence evidence that a disproportionate number of people with HIV co-infection have genotype 4 HCV compared with people without HIV co-infection.
## Table 13 Genotype by family origin

<table>
<thead>
<tr>
<th>HCV genotype</th>
<th>White or white British n (%)</th>
<th>Asian or Asian British n (%)</th>
<th>Black or black British n (%)</th>
<th>Other or mixed origin n (%)</th>
<th>Unknown n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>13,675 (81)</td>
<td>875 (5)</td>
<td>116 (1)</td>
<td>265 (2)</td>
<td>2023 (12)</td>
</tr>
<tr>
<td>2</td>
<td>1883 (84)</td>
<td>75 (3)</td>
<td>12 (1)</td>
<td>35 (2)</td>
<td>239 (11)</td>
</tr>
<tr>
<td>3</td>
<td>12,001 (72)</td>
<td>2894 (17)</td>
<td>37 (0.22)</td>
<td>146 (0.88)</td>
<td>1532 (9)</td>
</tr>
<tr>
<td>4</td>
<td>593 (44)</td>
<td>378 (28)</td>
<td>48 (4)</td>
<td>90 (7)</td>
<td>239 (18)</td>
</tr>
<tr>
<td>5</td>
<td>25 (53)</td>
<td>7 (15)</td>
<td>6 (13)</td>
<td>0 (0)</td>
<td>9 (19)</td>
</tr>
<tr>
<td>6</td>
<td>12 (19)</td>
<td>4 (6)</td>
<td>1 (2)</td>
<td>42 (66)</td>
<td>5 (8)</td>
</tr>
<tr>
<td>Non-1</td>
<td>46 (70)</td>
<td>3 (5)</td>
<td>0 (0)</td>
<td>1 (2)</td>
<td>16 (24)</td>
</tr>
<tr>
<td>Dual</td>
<td>13 (59)</td>
<td>6 (27)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>3 (14)</td>
</tr>
</tbody>
</table>

Abbreviation: HCV, hepatitis C virus.

### Company's additional evidence

#### 3.57
The company provided additional evidence in response to consultation. The company focused its response on:

- people with previously treated genotype 1 or 4 HCV with cirrhosis
- people with genotype 3 HCV that is unsuitable for interferon therapy.

#### 3.58
The company stated that the marketing authorisation allows some people with previously treated genotype 1 or 4 HCV with cirrhosis to have 12 weeks (rather than 24 weeks) of treatment with ledipasvir–sofosbuvir. It explained that these people are those 'deemed at low risk for clinical disease progression and who have subsequent retreatment options'. The company considered that the European Medicines Agency included this criterion so 'individual clinical judgement could determine those patients whose HCV would benefit from 12 weeks' treatment with ledipasvir–sofosbuvir'. However, the company sought advice from its clinical advisors to define 'low risk of clinical disease progression' and 'subsequent retreatment options' that could be used to identify these
people in clinical practice. The company stated that 12 weeks' treatment with ledipasvir–sofosbuvir should be considered if all the following criteria are met:

- Child–Pugh score of 6 or below (that is, class A)
- platelet count of 75,000/mm$^3$ or more
- no features of portal hypertension (for example, absence of oesophageal varices)
- no history of an HCV-associated decompensation episode
- not previously treated with an NS5A inhibitor (for example, ledipasvir or daclatasvir).

The company presented pooled SVR12 data for people with previously treated genotype 1 HCV with cirrhosis and a platelet count of 75,000/mm$^3$ or more from the ION studies. The company noted that people with a history of HCV-related decompensation episodes or who were previously treated with an NS5A inhibitor were excluded from the ION studies, and information on people with features of portal hypertension was not collected. The SVR12 rate for 12 weeks' ledipasvir–sofosbuvir was 96% (197 out of 206 people). The company presented an analysis for people with previously treated genotype 1 or 4 HCV with cirrhosis for 12 weeks' ledipasvir–sofosbuvir treatment 'deemed at low risk of clinical disease progression and who have subsequent retreatment options'. This analysis incorporated the approach taken in the ERG's exploratory analyses as preferred by the Committee (see section 4.11), and used the pooled SVR12 data from the ION studies (see table 14).

Table 14 Incremental cost-effectiveness results for people with previously treated genotype 1 or 4 HCV with cirrhosis deemed at low risk of clinical disease progression and who have subsequent retreatment options

<table>
<thead>
<tr>
<th>Option</th>
<th>Cardoso et al. 2010</th>
<th>Fattovich et al. 1997</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>QALYs</td>
<td>Costs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDV–SOF 12 weeks</td>
<td>9.61</td>
<td>£60,378</td>
</tr>
<tr>
<td>SOF+SMV</td>
<td>9.49</td>
<td>£79,754</td>
</tr>
<tr>
<td>SOF+PR</td>
<td>8.59</td>
<td>£63,193</td>
</tr>
</tbody>
</table>
### Table 15 Incremental cost-effectiveness results for genotype 3 HCV unsuitable for interferon therapy

<table>
<thead>
<tr>
<th>Option</th>
<th>Cardoso et al. 2010</th>
<th>Fattovich et al. 1997</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>QALYs</td>
<td>Costs</td>
</tr>
<tr>
<td>Previously untreated genotype 3 HCV with cirrhosis, unsuitable for interferon therapy¹</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDV–SOF+RBV 24 weeks</td>
<td>10.23</td>
<td>£102,645</td>
</tr>
<tr>
<td>SOF+R</td>
<td>9.87</td>
<td>£95,947</td>
</tr>
</tbody>
</table>

Abbreviations: BOC, boceprevir; ED, extended dominance; ICER, incremental cost-effectiveness ratio; LDV, ledipasvir; PR, peginterferon alfa + ribavirin; QALY, quality-adjusted life year; SMV, simeprevir; SOF, sofosbuvir; TVR, telaprevir.

Dominated – treatment gives fewer QALYs at greater cost than comparator.

Extended dominance – a combination of 2 of its comparators provides equal health at a reduced cost.

The company also presented updated ICERs using the approach taken in the ERG’s exploratory analyses for people with genotype 3 HCV whose HCV was unsuitable for interferon therapy (stratified by treatment history and presence of cirrhosis; see table 15). SVR12 data for people with previously untreated genotype 3 HCV were consistent with those presented in the company’s original submission (see table 3). However, the company updated its economic model to include SVR12 rather than SVR4 data for people with previously treated genotype 3 HCV. The company noted that in ELECTRON-2, people with previously treated genotype 3 HCV had an SVR12 of 89% (25 out of 28 people) with cirrhosis, and an SVR12 of 73% (16 out of 22 people) without cirrhosis.
### Previously treated genotype 3 HCV with cirrhosis, unsuitable for interferon therapy\(^1\)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>ICER</th>
<th>Cost ((\£))</th>
<th>Cost/QALY</th>
<th>ICER</th>
<th>Cost ((\£))</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDV–SOF+RBV 24 weeks</td>
<td>8.55</td>
<td>106,735</td>
<td>10,440</td>
<td>9.17</td>
<td>110,133</td>
</tr>
<tr>
<td>SOF+R</td>
<td>8.01</td>
<td>101,109</td>
<td>-</td>
<td>8.89</td>
<td>105,608</td>
</tr>
</tbody>
</table>

### Previously untreated genotype 3 HCV without cirrhosis, unsuitable for interferon therapy

<table>
<thead>
<tr>
<th>Treatment</th>
<th>ICER</th>
<th>Cost ((\£))</th>
<th>Cost/QALY</th>
<th>ICER</th>
<th>Cost ((\£))</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDV–SOF+RBV 12 weeks</td>
<td>17.24</td>
<td>42,997</td>
<td>10,549</td>
<td>17.24</td>
<td>42,997</td>
</tr>
<tr>
<td>No treatment</td>
<td>14.57</td>
<td>14,928</td>
<td>-</td>
<td>14.97</td>
<td>16,430</td>
</tr>
</tbody>
</table>

### Previously treated genotype 3 HCV without cirrhosis unsuitable for interferon therapy

<table>
<thead>
<tr>
<th>Treatment</th>
<th>ICER</th>
<th>Cost ((\£))</th>
<th>Cost/QALY</th>
<th>ICER</th>
<th>Cost ((\£))</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDV–SOF+RBV 24 weeks</td>
<td>15.97</td>
<td>84,109</td>
<td>33,631</td>
<td>16.01</td>
<td>84,234</td>
</tr>
<tr>
<td>No treatment</td>
<td>13.88</td>
<td>13,936</td>
<td>-</td>
<td>14.23</td>
<td>15,110</td>
</tr>
</tbody>
</table>

Abbreviations: ICER, incremental cost-effectiveness ratio; LDV, ledipasvir; QALY, quality-adjusted life year, RBV, ribavirin; SOF, sofosbuvir.

\(^1\) The company excluded 'no treatment' from the analysis without justification.

3.61 The company commented that the transition probabilities for compensated or decompensated cirrhosis to hepatocellular carcinoma from Cardoso et al. (2010) were more appropriate than from Fattovich et al. (1997). It stated this was because Cardoso et al. better reflected the relative risk reduction of developing hepatocellular carcinoma in people with compensated cirrhosis who had an SVR, compared with people with compensated cirrhosis who are untreated or without an SVR (80% [Cardoso] compared with 8.6% [Fattovich]). The company considered that this was supported by clinician opinion.

## ERG comments on company's additional evidence

3.62 The ERG’s clinical advisers suggested that there was no clear definition that could be used to identify people with previously treated genotype 1 or 4 HCV with cirrhosis deemed ‘at low risk for clinical disease progression and who have subsequent retreatment options’ in clinical practice. Therefore, the ERG urged caution in interpreting the company's ICERs for this subgroup.

3.63 The ERG was concerned about how people with previously untreated
genotype 3 HCV could be considered as 'intolerant' to or 'ineligible' for interferon therapy if they had no prior treatment.

3.64 The ERG was concerned that the company had not included 'no treatment' as an option in the previously treated genotype 3 HCV analyses. The ERG commented that when including 'no treatment' in the analysis of previously treated genotype 3 HCV that was unsuitable for interferon therapy in people with cirrhosis, sofosbuvir plus ribavirin was extendedly dominated (that is, a combination of 2 of its comparators provides equal health at a reduced cost). The ERG’s ICER for ledipasvir–sofosbuvir in a fully incremental analysis ranged from £19,668 per QALY gained (using Cardoso) to £33,148 per QALY gained (using Fattovich) compared with 'no treatment'.

3.65 Full details of all the evidence are available.
4 Consideration of the evidence

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of ledipasvir-sofosbuvir, having considered evidence on the nature of chronic hepatitis C and the value placed on the benefits of ledipasvir–sofosbuvir by people with the condition, those who represent them, and clinical experts. It also took into account the effective use of NHS resources.

4.1 The Committee heard from the clinical and patient experts about the nature of chronic hepatitis C. The patient expert stated that some people with chronic hepatitis C do not have any symptoms, but others may have chronic fatigue, mood swings and symptoms of sexual dysfunction. The severity of symptoms does not depend on the stage of fibrosis. The clinical and patient experts also commented that the psychological effect of having chronic hepatitis C can impair people’s social life and ability to work, and that people can have anxiety about transmitting the virus. There is also stigma about having chronic hepatitis C because it is associated with drug use. The Committee heard from the patient expert that people who have chronic hepatitis C are a disadvantaged population. The patient expert estimated that around 3% of the people infected with chronic hepatitis C take active treatment for their condition, but anticipated that the availability of clinically effective treatment options of short duration, such as ledipasvir–sofosbuvir, will encourage more people to seek diagnosis and treatment. It would also allow access to treatment for people who have found it difficult to access treatment before, such as people in prison, people who use injectable drugs and migrant populations. The Committee recognised the effect of chronic hepatitis C on the lives of people with the virus. It concluded that treatments that give very high levels of sustained virological response (which is considered equivalent to a cure), and so help reduce the rate of hepatitis C virus (HCV) transmission and the stigma associated with having chronic hepatitis C, are of major importance.

4.2 The Committee discussed the clinical management of chronic hepatitis C in adults. It heard from the clinical experts that treatment decisions and response to treatment are influenced by HCV genotype, level of liver damage, comorbidities and treatment history. The Committee was aware that ledipasvir–sofosbuvir has a marketing authorisation in the UK for adults with genotypes 1, 3 and 4 HCV. For people with genotype 1 HCV, the Committee heard that boceprevir plus peginterferon alfa and ribavirin or telaprevir plus
peginterferon alfa and ribavirin (see NICE's technology appraisal guidance on bocceprevir for the treatment of genotype 1 chronic hepatitis C and telaprevir for the treatment of genotype 1 chronic hepatitis C) are commonly used, and that for people with genotype 1, 3 or 4 HCV, peginterferon alfa plus ribavirin is also used in clinical practice (see NICE's technology appraisal guidance on peginterferon alfa and ribavirin for the treatment of chronic hepatitis C, peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C and interferon alfa and ribavirin for the treatment of chronic hepatitis C). The clinical experts highlighted that some people with chronic hepatitis C would choose not to have treatment with peginterferon alfa plus ribavirin because it can be associated with severe side effects, such as fatigue, neuropsychological effects and flu-like symptoms. The Committee also heard from the clinical and patient experts that interferon-based treatment may cause chronic side effects (such as insulin-dependent diabetes) that need additional long-term management. It may therefore pose another barrier to people starting and completing treatment. Without treatment people risk further disease progression, for example, to cirrhosis. The clinical experts commented that watchful waiting may be considered an appropriate option for some people. The clinical experts suggested that this option would be likely to become a less common choice in the era of interferon-free treatments, particularly because of the possibility that some people could be lost to follow-up. The Committee recognised the importance of having further treatment options available for people with chronic hepatitis C, and that an interferon-free treatment, such as ledipasvir–sofosbuvir, would provide a valuable treatment option.

4.3 The Committee discussed whether the technologies in the NICE scope that had recently been granted a marketing authorisation for treating adults with chronic hepatitis C were established clinical practice in England. The Committee was aware that:
• For people with genotype 1 or 4 chronic hepatitis C, whose disease has or has not been previously treated, NICE's technology appraisal guidance on simeprevir for treating chronic hepatitis C recommends simeprevir plus peginterferon alfa and ribavirin as an option.

For people with genotypes 1–6 chronic hepatitis C, whose disease has or has not been previously treated, NICE's technology appraisal guidance on sofosbuvir for treating chronic hepatitis C recommends sofosbuvir plus ribavirin, with or without peginterferon alfa, as an option for some people.

The patient expert commented that all current treatment options for people with genotype 1 or 4 HCV involve injecting interferon weekly, including those recommended in NICE's technology appraisal guidance on sofosbuvir (given sofosbuvir plus ribavirin is not recommended for people with genotype 1 or 4 HCV) and on simeprevir. The Committee acknowledged that the marketing authorisation for ledipasvir–sofosbuvir offers people the option to have shortened courses of treatment, without peginterferon alfa, thereby avoiding the adverse events associated with interferon-based therapy. The Committee was also aware that the oral combination of simeprevir plus sofosbuvir has not been appraised by NICE. Therefore it could not be considered as established practice. The Committee concluded that sofosbuvir plus ribavirin, with or without peginterferon alfa, and simeprevir plus peginterferon alfa and ribavirin, as recommended in NICE guidance, were relevant comparators for ledipasvir–sofosbuvir.

**Clinical effectiveness**

4.4 The Committee discussed the clinical effectiveness evidence for ledipasvir–sofosbuvir in people with genotype 1 HCV. The Committee was aware that most people enrolled into the ION studies had genotype 1 HCV without cirrhosis, and that the sustained virological responses at 12 weeks (SVR12) for people with and without cirrhosis were similar, irrespective of treatment history (that is, previously untreated or treated HCV). The Committee noted that no head-to-head studies of ledipasvir–sofosbuvir with any of the comparators listed in the scope were available, and the ION studies used historical controls. The company highlighted that of the 1952 people enrolled into the 3 phase III ION studies, 96.7% were cured of HCV and only 1.8% had virological relapse after treatment. The Committee heard from the clinical and patient experts that the results in people with genotype 1 HCV were impressive. The clinical experts stated that the SVR rates from the
The Committee discussed the clinical effectiveness evidence for ledipasvir–sofosbuvir in people with genotype 4 HCV. The Committee noted that there were limited data available in people with genotype 4 HCV. It agreed that this increased the uncertainty about whether the SVR rates from the genotype 4 HCV population would be seen in clinical practice. It also questioned whether the SVR rates for people with genotype 1 HCV could be generalised to people with genotype 4 HCV. The Committee acknowledged the company’s view that people with genotypes 1 and 4 HCV have responded similarly to treatment in the past, and noted that the European Medicines Agency considered that the efficacy of ledipasvir–sofosbuvir for genotype 1 HCV in the ION studies was relevant to genotype 4 HCV. The Committee remained concerned about the lack of head-to-head trials, and the small numbers of people with genotype 4 HCV included in the evidence base. However, it concluded that it was satisfied that ledipasvir–sofosbuvir would potentially demonstrate a similar treatment effect in people with genotype 4 HCV to that shown for people with genotype 1 HCV (with or without cirrhosis).

The Committee discussed the treatment durations for ledipasvir–sofosbuvir in people with genotype 1 or 4 HCV without cirrhosis. The Committee was aware that the marketing authorisation recommends durations of 8, 12 and 24 weeks of ledipasvir–sofosbuvir, depending on genotype, treatment history, risk of progression and cirrhosis status. It recognised that the company had submitted a post-hoc analysis to identify people for whom 8 weeks of treatment would be appropriate (see section 3.6). These were people with genotype 1 HCV that was previously untreated, who do not have cirrhosis and who have a viral load of less than 6 million international units (IU)/ml. However, the Committee was aware that although the marketing authorisation did specify that previously untreated genotype 1 HCV was suitable for 8 weeks’ treatment, the viral load criterion
was not specified. The Committee noted that the populations defined by the European Medicines Agency for each treatment duration of ledipasvir–sofosbuvir recommended in the marketing authorisation were open to interpretation, and heard from the clinical experts that these groups were not clearly defined in clinical practice. The Committee heard from the company that the European Medicines Agency had taken a conservative approach by recommending longer treatment durations, because the ION studies did not show any additional harm (that is, there was a similar risk–benefit profile) from increasing the duration of treatment from 8 to 12 weeks, or from 12 to 24 weeks. The company commented further that increasing the treatment duration only 'marginally increased the SVR rates'. The clinical experts stated that overall, the SVR rates in the ION studies were impressive irrespective of treatment duration, and that in general people would prefer to have shorter treatments. The Committee concluded that ledipasvir–sofosbuvir appeared similarly effective across the different durations used, and that it would make recommendations for each treatment duration for people with genotype 1 or 4 HCV without cirrhosis.

4.7 The Committee discussed the treatment durations for people with genotype 1 or 4 HCV with cirrhosis. The Committee noted that the marketing authorisation recommends 12 weeks of ledipasvir–sofosbuvir rather than 24 weeks of ledipasvir–sofosbuvir for these populations if the patient is 'deemed at low risk for clinical disease progression and has subsequent retreatment options'. The Committee heard from the company that it considered this criterion was vague in the marketing authorisation because the regulators wanted to provide clinicians with some flexibility when identifying people with cirrhosis who were eligible for 12 weeks' treatment with ledipasvir–sofosbuvir. The clinical experts at the first Appraisal Committee meeting agreed that it was challenging to distinguish between those with a high risk or low risk of clinical disease progression without any specific biomarkers. The clinical experts emphasised that 12 weeks of ledipasvir–sofosbuvir offers major advantages over currently available treatment options, especially in populations with historically difficult-to-treat HCV, and that the data from the ION studies showed benefits for 12 weeks' treatment in most people. The Committee acknowledged that 12 weeks' treatment with ledipasvir–sofosbuvir could be appropriate for people with genotype 1 or 4 HCV with cirrhosis. However, the Committee considered that there was a need to define 'low risk of clinical disease progression and subsequent retreatment options' that could be used to identify people with
previously treated genotype 1 or 4 HCV with cirrhosis eligible for 12 weeks' treatment with ledipasvir–sofosbuvir in clinical practice. In response to consultation, a clinical expert commented that HCV treatment centres were well placed to make sound clinical judgements to identify people thought to be at low risk of clinical disease progression and with subsequent retreatment options through multidisciplinary teams. The Committee was aware that the company, in its response to consultation, had provided a definition for people with previously treated genotype 1 or 4 HCV with cirrhosis who were 'deemed at low risk of clinical disease progression and who have subsequent retreatment options' that could be used to identify these people in clinical practice (see section 3.58). The Committee understood from the clinical experts at the third Appraisal Committee meeting that all of the company's criteria were routinely assessed in clinical practice in England (for example, Child–Pugh score, platelet count, features of portal hypertension). The Committee agreed that it could make a recommendation for 12 weeks' ledipasvir–sofosbuvir for people with previously treated genotype 1 or 4 HCV with cirrhosis using the company's definition for 'low risk of clinical progression and subsequent retreatment options'.

4.8 The Committee discussed the clinical effectiveness evidence for ledipasvir–sofosbuvir plus ribavirin in people with genotype 3 HCV. The Committee was aware that limited evidence was available for people with genotype 3 HCV, particularly for the population with previously untreated HCV (n=26). The Committee acknowledged that at the time of the company's original submission (and as included in the company's economic model) data for sustained virological response at 4 weeks (SVR4) were only available for 50 people with previously treated genotype 3 HCV. The Committee heard from the company that ELECTRON-2 was a phase II study, so small numbers of people were inevitable, but that SVR12 data were now available for the previously treated HCV population. These showed that only 1 of the 42 people who had an SVR4 did not have an SVR12. The Committee understood that people in ELECTRON-2 had 12 weeks of ledipasvir–sofosbuvir plus ribavirin, but the marketing authorisation recommends 24 weeks of treatment in people with cirrhosis or who had prior treatment. The company commented that the European Medicines Agency conservatively recommended 24 weeks' treatment because this was historically a population with difficult-to-treat HCV, and because of the limited trial data available. The Committee heard from the clinical experts that it was difficult to determine whether the SVR rates in
ELECTRON-2 would be seen in clinical practice, because of the small patient numbers, but emphasised that the initial 12-week results were impressive, and they did not signal any safety issues from extending the treatment duration to 24 weeks. The Committee concluded that although there was uncertainty about the robustness of the evidence base in people with genotype 3 HCV, there was sufficient evidence to consider ledipasvir–sofosbuvir plus ribavirin in people with genotype 3 HCV.

4.9 The Committee discussed the company's approach to estimating the effectiveness of ledipasvir–sofosbuvir (with or without ribavirin) relative to the comparators in the scope. The Committee noted that the company did not attempt a mixed treatment comparison because the ledipasvir–sofosbuvir trials were single arm. However it understood from the Evidence Review Group (ERG) that it would have been possible to do a mixed treatment comparison for the comparators for genotype 1 HCV. The Committee commented that the company's naive indirect comparison approach was not robust and leads to considerable uncertainty in determining the size of the true treatment effect.

The Committee understood from previous NICE technology appraisals that the SVR rates were likely to depend on the characteristics of the populations recruited into the studies, particularly for comparator therapies such as peginterferon alfa plus ribavirin, which may affect the relative treatment effect. The Committee was concerned that the company had selected SVR rates from single studies without justification, particularly because this uncertainty was not captured in the company's estimates of cost effectiveness. The Committee heard from the company that a network could not be formed for all technologies in the relevant populations because of data limitations. The company also stated that the cost-effectiveness results were not sensitive to the choice of SVR rates for the comparators used in its economic model. In addition, the company considered that because SVR is a hard end point, it did not consider its approach to increase uncertainty. However, the Committee heard from the ERG that the SVR rates of comparators did not need to change by much for potential conclusions around the cost effectiveness to change. The Committee concluded that the company's evidence for estimating the relative effectiveness of ledipasvir–sofosbuvir (with or without ribavirin) in people with genotype 1, 3 or 4 HCV was not robust, and therefore this uncertainty should be taken into account in the decision-making.
Cost effectiveness

4.10 The Committee considered the company’s economic model, the ERG’s critique and the ERG’s exploratory analyses. The Committee noted that the company’s economic model structure differed slightly from that used in previous NICE technology appraisals for hepatitis C. This was because people with mild and moderate chronic hepatitis C were grouped within a single health state, and therefore the company’s model distinguished only between people with and without cirrhosis. However, the Committee heard from the company that its economic model structure was similar to that in NICE’s technology appraisal guidance on sofosbuvir for treating chronic hepatitis C. The clinical experts acknowledged that the model structure was consistent with how people are diagnosed in clinical practice. The Committee heard from the clinical experts that in the past, invasive liver biopsies were used to diagnose mild, moderate or severe hepatitis C. However, current practice involves less invasive diagnostic tests that do not differentiate between mild and moderate disease and can distinguish only between cirrhosis and no cirrhosis. The Committee concluded that the approach taken by the company was appropriate.

4.11 The Committee discussed the company’s weighted-average approach (or ‘blended comparison’). The Committee noted that the company’s base-case analysis presented incremental cost-effectiveness ratios (ICERs) for a combined group of people with and without cirrhosis. The Committee was aware that the presence of cirrhosis affects the recommended regimen for ledipasvir–sofosbuvir and a person’s likelihood of an SVR with comparator treatments, and therefore the cost effectiveness of treatment with ledipasvir–sofosbuvir. The Committee acknowledged that the patient numbers underpinning the clinical evidence used in the company’s economic model were small for the groups of people with cirrhosis (including those with genotype 1 HCV), and that the SVR rates were relatively similar to those reported for ledipasvir–sofosbuvir in people without cirrhosis. However, the Committee concluded that it was appropriate to use the approach taken in the ERG’s exploratory analyses, in line with the marketing authorisation, which considered people with and without cirrhosis separately, and estimated the cost effectiveness of ledipasvir–sofosbuvir for each recommended treatment duration.

4.12 The Committee discussed the baseline characteristics of the population
included in the company's economic model. The Committee noted that the ICERs were sensitive to the mean starting age used in the model. It was aware that the mean starting age was 40 years (for previously untreated HCV) and 45 years (for previously treated HCV) based on data from the HCV Research UK database, but the mean age of people in the ION studies was between 51 and 57 years. The Committee heard from the company that it chose to use the mean age from the HCV Research UK database because it more closely reflected the clinical population in England (and included a larger group of people) than the mean age of the population in the predominantly US-based ION studies. The Committee concluded that the mean age from the HCV Research UK database was more relevant to the clinical population in England.

4.13 The Committee discussed the transition probabilities used in the company's economic model. The Committee understood that the company had used transition probabilities for compensated or decompensated cirrhosis to hepatocellular carcinoma from Cardoso et al. (2010), which the company used in its revised economic model after the first consultation for NICE’s technology appraisal guidance on sofosbuvir for treating chronic hepatitis C. It noted that in response to consultation, the company stated that it considered Cardoso more appropriate than Fattovich et al. (1997) (see section 3.61). The Committee noted that the ERG’s exploratory analysis included transition probabilities from Fattovich et al., and was aware from the NICE guidance on sofosbuvir that although each source was associated with significant uncertainty they each had some face validity. The Committee was aware of a further source for the transition probabilities (Bruno et al. 2007), from sofosbuvir for treating chronic hepatitis C, which more closely reflected those presented in Fattovich than in Cardoso. The Committee also highlighted that there was further uncertainty relating to the company’s assumption that these transition probabilities were independent of genotype. The Committee considered that in clinical practice, the rates of disease progression, and hence the transition probabilities, were likely to differ between genotype 1 or 4 HCV and genotype 3 HCV. The Committee considered that Cardoso et al. was an acceptable source for transition probabilities, but that exploring alternative sources for transition probabilities, such as Fattovich et al., was also valuable because both values could be considered plausible. The Committee concluded that the transition probabilities may lie somewhere between the Cardoso et al. and Fattovich et al. estimates, and therefore both sources should be taken into account in the decision-making.
The Committee discussed the utility values used in the company's model. The Committee acknowledged that health-related quality of life was assessed in the ION studies using the SF-36 questionnaire and that none of the clinical trials collected data using the EQ-5D. The Committee noted that the company had therefore included a utility benefit of 0.04 for people who had an SVR, taken from Vera-Llonch et al. (2013). It noted that this was estimated with the US EQ-5D tariff, rather than the UK EQ-5D tariff (Wright et al. 2006, which estimated a utility benefit of 0.05). The Committee heard from the company that it chose Vera-Llonch et al. for the utility benefit estimate because this was the most recent source used in its economic model for NICE's technology appraisal guidance on sofosbuvir for treating chronic hepatitis C. The Committee was aware that the ERG's exploratory analysis showed that the ICERs reduced slightly in favour of ledipasvir–sofosbuvir when using the utility benefit from Wright et al. However, it also noted that the exploratory analysis by the ERG, which removed a utility benefit associated with SVR, showed the ICERs for ledipasvir–sofosbuvir substantially increased. The company stated that it was unable to include utility estimates from the ION studies because data were not available at the time of its evidence submission. The Committee agreed that the health-related quality-of-life data available from the ION studies suggested some benefit with ledipasvir–sofosbuvir, but the results were not consistent across the 3 phase III studies and the 4 questionnaires assessed so it was difficult to approximate how much benefit people were likely to gain. In addition, the Committee was concerned that the utility accrued over a person's lifetime in the company's model was likely to be overestimated because the utility values were not adjusted for increasing age, and therefore the utility benefit from an SVR was assumed to be maintained until death. The Committee concluded that it would have preferred to have seen the utility values determined directly from the ION studies and to have the utility values in the model adjusted for increasing age, but it was prepared to accept the utility benefit from Vera-Llonch et al. in the economic analyses.

The Committee discussed whether it was appropriate to exclude the health effects from reinfection and transmission of HCV in the analysis. The Committee noted that excluding reinfection may overestimate the health benefits of more effective treatments and underestimate their costs, because people would be retreated with other therapies in clinical practice. The Committee understood from the clinical experts that the rate of reinfection was relatively small (approximately 1%). However, the Committee also
acknowledged that most people who do not have an SVR after treatment were also likely to have further treatment in clinical practice (including people whose HCV relapses after having an initial SVR), and this too had not been accounted for in the company’s economic model. The Committee recognised that excluding transmission of HCV may underestimate the health benefits of more effective treatments. The Committee commented that the ICERs were associated with some uncertainty because these health effects were omitted. It would have preferred the company to explore their inclusion further, but appreciated that this would have needed a different (and potentially more complex) model structure. The Committee concluded that ICERs excluding the health effects of reinfection and transmission of HCV were acceptable to use but this uncertainty should be taken into account in the decision-making.

4.16 The Committee acknowledged that all the ICERs presented depended on the clinical effectiveness data, which was associated with considerable uncertainty, namely:

- the clinical study designs (these were open-label, non-randomised controlled evidence, with no head-to-head studies)

- the selection of SVR rates for comparators from single studies (given that patient and clinical characteristics influence SVR rates for each treatment differently and within each HCV genotype, and the sensitivity of the ICERs to the choice of SVR rates as shown in the ERG’s exploratory threshold analysis)

- the use of an uncontrolled naive indirect comparison to estimate the relative effectiveness of ledipasvir–sofosbuvir and its comparators.

The Committee heard from the clinical experts that in clinical practice most people who do not have an SVR12 after a course of treatment are likely to have further treatment. The Committee noted that for all the ICERs presented, retreatment was not accounted for and it was uncertain whether this was likely to increase or decrease the cost effectiveness of ledipasvir–sofosbuvir. The Committee concluded that all ICERs presented are associated with considerable uncertainty.
Genotypes 1 and 4

Previously untreated HCV without cirrhosis

4.17 The Committee discussed the ICERs for ledipasvir–sofosbuvir in people with previously untreated genotype 1 HCV without cirrhosis. The Committee highlighted that the ERG’s ICERs from the incremental analyses for 8 weeks and 12 weeks of ledipasvir–sofosbuvir in people with previously untreated genotype 1 HCV without cirrhosis were £9000 (compared with peginterferon alfa plus ribavirin) and £23,000 (compared with simeprevir plus peginterferon alfa and ribavirin) per quality-adjusted life year (QALY) gained respectively. The Committee inferred that the ICERs estimated by the ERG increased by approximately £3000 per QALY gained when using the transition probabilities from Fattovich et al. (1997) rather than from Cardoso et al. (2010); see table 11. On balance, the Committee thought that the ICERs for ledipasvir–sofosbuvir may increase if the company had accounted for the additional uncertainty associated with the clinical- and cost-effectiveness evidence. The Committee concluded that 12 weeks of ledipasvir–sofosbuvir could not be considered a cost-effective use of NHS resources in this population. However, it concluded that 8 weeks of ledipasvir–sofosbuvir could be considered a cost-effective use of NHS resources for people with previously untreated genotype 1 HCV without cirrhosis.

4.18 The Committee discussed the ICERs for ledipasvir–sofosbuvir in people with previously untreated genotype 4 HCV without cirrhosis. It noted that the marketing authorisation for ledipasvir–sofosbuvir does not recommend the 8-week treatment duration for the genotype 4 HCV population, and therefore it could not make a recommendation for this treatment duration in people with genotype 4 HCV. The Committee reiterated the uncertainties associated with the clinical evidence included in the economic modelling (see section 4.16), and noted the specific uncertainty about the small patient numbers for the data available in people with genotype 4 HCV (see section 4.5) so the company used SVR rates based on people with genotype 1 HCV, which may not be representative. However, it agreed that it would consider the ICERs presented for people with genotype 4 HCV that used data from people with genotype 1 HCV (that is, the ICERs available for people with genotype 4 HCV were the same as those estimated for people with genotype 1 HCV). The Committee was also aware that boceprevir and telaprevir have a marketing authorisation in the
UK for treating genotype 1 HCV only, and therefore were not appropriate comparators for ledipasvir–sofosbuvir in people with genotype 4 HCV. The Committee highlighted its conclusions for 12 weeks of ledipasvir–sofosbuvir in people with previously untreated genotype 1 HCV without cirrhosis (see section 4.17), and concluded that 12 weeks of ledipasvir–sofosbuvir in people with previously untreated genotype 4 HCV without cirrhosis could not be considered a cost-effective use of NHS resources.

Previously untreated HCV with compensated cirrhosis

4.19 The Committee discussed the ICERs for ledipasvir–sofosbuvir in people with previously untreated genotype 1 or 4 HCV with cirrhosis. The Committee recognised that a similar quality of evidence had been presented for the 12-week and 24-week treatment durations for the genotype 1 HCV population from the ION studies, which showed relatively similar SVR rates and risk of relapse between the treatment durations. However, the Committee highlighted that the data available for people with cirrhosis from the ION studies were based on small patient numbers. The Committee highlighted that the ERG's ICERs from the incremental analyses for ledipasvir–sofosbuvir in people with previously untreated genotype 1 or 4 HCV with cirrhosis were £5000 (12 weeks of treatment, compared with no treatment) and £45,000 (24 weeks of treatment, compared with sofosbuvir plus peginterferon alfa and ribavirin) per QALY gained. The Committee understood that the ERG's ICERs for this population were highly sensitive to the evidence source used for transition probabilities, and that they increased approximately 2-fold when using the transition probabilities from Fattovich et al. (1997) rather than from Cardoso et al. (2010); see table 11. On balance, the Committee concluded that only 12-week ledipasvir–sofosbuvir treatment could be considered a cost-effective use of NHS resources in people with previously untreated genotype 1 or 4 HCV with cirrhosis.

Previously treated HCV without cirrhosis

4.20 The Committee discussed the ICERs for ledipasvir–sofosbuvir in people with previously treated genotype 1 or 4 HCV without cirrhosis. The Committee highlighted that the ERG's ICERs from the incremental analyses for ledipasvir–sofosbuvir in people with previously treated genotype 1 or 4 HCV without cirrhosis were £17,000 (12 weeks of treatment, compared with no treatment) and £77,500 (24 weeks of treatment, compared with simeprevir plus...
The Committee noted that the ERG’s estimated ICER for 12-week treatment increased by approximately £2000 per QALY gained when using the transition probabilities from Fattovich et al. rather than from Cardoso et al. (see Table 11). On balance, the Committee concluded that only 12-week ledipasvir–sofosbuvir treatment could be considered a cost-effective use of NHS resources in people with previously treated genotype 1 or 4 HCV without cirrhosis.

Previously treated HCV with compensated cirrhosis

The Committee discussed the ICERs for ledipasvir–sofosbuvir in people with previously treated genotype 1 or 4 HCV with cirrhosis. The Committee received clarification from the European Medicines Agency that the marketing authorisation did not exclude 12 weeks’ treatment for people with previously treated HCV genotype 1 or 4 HCV with cirrhosis, but it was only recommended in people ‘at low risk for clinical disease progression and who have subsequent retreatment options’. The Committee noted that the company had defined this criterion and identified the previously treated genotype 1 or 4 HCV population who would be eligible for 12 weeks’ treatment (see section 4.7). The Committee considered the company’s SVR12 data and ICERs for 12 weeks’ treatment for people with previously treated genotype 1 or 4 HCV in its response to consultation (see sections 3.58 and 3.59). The Committee noted that the company’s ICERs from the incremental analyses for 12 weeks’ ledipasvir–sofosbuvir in people with previously treated genotype 1 or 4 HCV with cirrhosis deemed at low risk of clinical disease progression and who have subsequent retreatment options were approximately £4500 per QALY gained compared with no treatment when using the transition probabilities from either Fattovich et al. (1997) or Cardoso et al. (2010). The Committee concluded that 12 weeks’ ledipasvir–sofosbuvir treatment could be considered a cost-effective use of NHS resources in people with previously treated genotype 1 or 4 HCV with cirrhosis, only if all the following criteria are met:

- Child–Pugh score of 6 or below (that is, class A)
- platelet count of 75,000/mm$^3$ or more
- no features of portal hypertension (for example, absence of oesophageal varices)
- no history of an HCV-associated decompensation episode
• not previously treated with an NS5A inhibitor (for example, ledipasvir or daclatasvir).

4.22 The Committee noted that the ERG’s estimated ICER for 24 weeks of ledipasvir–sofosbuvir in people with previously treated genotype 1 or 4 HCV with cirrhosis was £32,500 per QALY gained (compared with sofosbuvir plus peginterferon alfa and ribavirin). The Committee understood that the ERG’s estimated ICERs for this population were highly sensitive to the evidence source used for transition probabilities, and that they increased approximately 2-fold when using the transition probabilities from Fattovich et al. (1997) rather than from Cardoso et al. (2010); see table 11. The Committee concluded that 24-week ledipasvir–sofosbuvir treatment could not be considered a cost-effective use of NHS resources in people with previously treated genotype 1 or 4 HCV with cirrhosis.

Genotype 3

4.23 The Committee discussed the ICERs for ledipasvir–sofosbuvir plus ribavirin in people with genotype 3 HCV. The Committee noted that the marketing authorisation only recommends a treatment duration (24 weeks) for people with cirrhosis or people who have had treatment before in the genotype 3 HCV population, but not for previously untreated HCV and people who do not have cirrhosis. The Committee received clarification from the European Medicines Agency that people with previously untreated genotype 3 HCV without cirrhosis were omitted from the recommendations in the marketing authorisation because the data were from small numbers of people and there was a lack of a direct comparison with 24 weeks' sofosbuvir plus ribavirin. The European Medicines Agency further clarified that if people with previously untreated genotype 3 HCV without cirrhosis were to be treated with ledipasvir–sofosbuvir, 'a conservative 24 weeks of therapy was advised'. The Committee emphasised their concerns about the robustness of the evidence base in people with genotype 3 HCV (see section 4.8), and concluded that the uncertainties in the methods used to estimate the relative effectiveness, and the uncertainty of excluding further treatment in the economic modelling, still applied to its decision-making for people with genotype 3 HCV (see section 4.16).

Previously untreated HCV

4.24 The Committee noted that all the ICERs presented for ledipasvir–sofosbuvir for
people with previously untreated genotype 3 HCV without cirrhosis (based on 12 weeks' treatment rather than the advised 24 weeks' treatment) or with cirrhosis (24 weeks' treatment) were over £30,000 per QALY gained (see tables 11 and 12). The Committee considered it could only make a recommendation for 24 weeks of ledipasvir–sofosbuvir given the clarification response NICE received from the European Medicines Agency (see section 4.23). The Committee concluded that 24 weeks of ledipasvir–sofosbuvir plus ribavirin treatment could not be considered a cost-effective use of NHS resources in people with previously untreated genotype 3 HCV.

4.25 The Committee considered the company's response to consultation, which presented cost-effectiveness analyses for the subgroup of people with previously untreated genotype 3 HCV for whom interferon is unsuitable (see table 15). The Committee acknowledged that some people with previously untreated HCV may be ineligible for interferon therapy because it may be contraindicated, as specified in its summary of product characteristics. However, the Committee agreed that people with previously untreated HCV could not be considered intolerant to interferon. The Committee noted that for people without cirrhosis the ICERs ranged from £10,500 (Cardoso et al. 2010) to £11,700 (Fattovich et al. 1997) per QALY gained compared with no treatment. However, the Committee further noted that these analyses included 12 weeks rather than 24 weeks of treatment with ledipasvir–sofosbuvir. The Committee agreed, given that 12 weeks of treatment is outside the marketing authorisation, it could not make a recommendation for this subgroup using these analyses. The Committee considered the ICERs for those with cirrhosis, which ranged from £19,000 (Cardoso) to £33,100 (Fattovich) per QALY gained, for 24 weeks of ledipasvir–sofosbuvir compared with sofosbuvir plus ribavirin. Taking into account the uncertainties that could increase the ICER further (see section 4.23), the Committee agreed that 24 weeks of ledipasvir–sofosbuvir plus ribavirin treatment could not be considered a cost-effective use of NHS resources for people with previously untreated genotype 3 HCV who have cirrhosis and for whom interferon is unsuitable.

Previously treated HCV

4.26 The Committee noted that all the ICERs presented for people with previously treated genotype 3 HCV without cirrhosis (24 weeks' treatment) were over £30,000 per QALY gained (see table 11). The Committee concluded that
24 weeks of ledipasvir–sofosbuvir plus ribavirin treatment could not be considered a cost-effective use of NHS resources in people with previously treated genotype 3 HCV.

4.27 The Committee considered the company’s response to consultation, which presented revised cost-effectiveness analyses for a subgroup of people with previously treated genotype 3 HCV for whom interferon is unsuitable (see table 15). The Committee noted that the ICERs presented for people without cirrhosis were over £30,000 per QALY gained compared with no treatment. The Committee was aware that the company had omitted ‘no treatment’ as a comparator from the analysis of the population with cirrhosis. The Committee agreed that ‘no treatment’ was a relevant comparator and should have been included in the company’s additional analyses. The Committee noted that for people with previously treated genotype 3 HCV with cirrhosis for whom interferon is unsuitable, the ERG explored including ‘no treatment’ as a comparator in the incremental analysis, and estimated an ICER of £19,500 per QALY gained for 24 weeks of ledipasvir–sofosbuvir plus ribavirin compared with no treatment (see section 3.63). The Committee was aware that this ICER increased to £33,000 per QALY gained when using the transition probabilities from Fattovich et al. (1997) rather than from Cardoso et al. (2010). On balance, the Committee agreed that the ICER for ledipasvir–sofosbuvir plus ribavirin in people with previously treated genotype 3 HCV with cirrhosis for whom interferon therapy is unsuitable, may increase if the company had accounted for the additional uncertainty associated with the clinical- and cost-effectiveness evidence. The Committee agreed that 24 weeks of ledipasvir–sofosbuvir plus ribavirin treatment could not be considered a cost-effective use of NHS resources in people with previously treated genotype 3 HCV for whom interferon is unsuitable.

People co-infected with HIV

4.28 The Committee discussed whether the evidence submitted by the company allowed it to make recommendations for people co-infected with HIV. It noted that the clinical effectiveness evidence presented in the company’s submission was from a single-centre, open-label, ongoing phase II study in adults with previously untreated genotype 1 HCV, co-infected with HIV and without cirrhosis. The Committee acknowledged that the interim results of this study suggested that the SVR12 in people with HCV and HIV co-infection was similar
to that seen in people with HCV mono-infection. The Committee was aware that the company had not submitted cost-effectiveness estimates for people co-infected with HIV and that the company considered this to be conservative because people with HCV who are co-infected with HIV are likely to progress to severe health states more quickly if left untreated than people with HCV mono-infection. The company stated that therefore ledipasvir–sofosbuvir was more likely to be cost effective in this population. However, the Committee noted that this assumption did not acknowledge other causes of mortality that were also likely to influence the cost-effectiveness results. The Committee understood that the ledipasvir–sofosbuvir summary of product characteristics states that people with HCV and HIV co-infection should have the same treatment as people with HCV mono-infection. On balance, the Committee concluded that it was reasonable to extend the recommendations made for the mono-infected group to those co-infected with HCV and HIV. However, the Committee agreed that future modelling and economic analyses should be presented separately for this population.

People with advanced liver disease and after liver transplant

4.29 The Committee discussed whether the evidence submitted by the company allowed it to make recommendations for people with advanced liver disease and after liver transplant. The Committee highlighted that the marketing authorisation for ledipasvir–sofosbuvir recommends only 24 weeks of treatment plus ribavirin in people with advanced liver disease and after liver transplant. It noted that the company submitted clinical effectiveness evidence for this group using SVR4 data from 1 multicentre open-label, phase II non-randomised controlled trial in adults with genotype 1 or 4 HCV, but had not explored the cost effectiveness of 24 weeks of ledipasvir–sofosbuvir plus ribavirin in people with advanced liver disease and after liver transplant. The Committee was aware that the company estimated the cost effectiveness in this population for NHS England when developing an interim commissioning policy for this group of people. The Committee heard from the company that it had not presented these estimates in its evidence submission because they were based on a simplified assumption that within 1 year all people with compensated cirrhosis have decompensated cirrhosis, and were not based on evidence. The Committee noted that the ICERs in the ERG’s exploratory analyses, which explored the use of 24 weeks' ledipasvir–sofosbuvir (with or without ribavirin
and across all HCV genotypes, see sections 4.20–22 and 4.24–4.27), were substantially higher than the range that could be considered a cost-effective use of NHS resources. On balance, the Committee concluded that without cost-effectiveness estimates it was unable to make recommendations for ledipasvir–sofosbuvir plus ribavirin in people with advanced liver disease and after liver transplant.

Innovation

4.30 The Committee discussed whether ledipasvir–sofosbuvir could be considered innovative, and whether the company's economic analysis had captured all changes in health-related quality of life. The Committee agreed that compared with current treatment, ledipasvir–sofosbuvir offers oral, shortened, interferon-free treatment, which is particularly important to people, and a major development in the clinical management of chronic hepatitis C. The Committee therefore acknowledged that ledipasvir–sofosbuvir is a valuable new therapy for treating chronic hepatitis C. The Committee agreed that there were other benefits for people with hepatitis C (for example, possible regression of fibrosis) and wider benefits to society (for example, reduced transmission of HCV [see section 4.15], improved earning capacity) that were not captured in the QALY calculation and that, if taken into account, were likely to decrease the ICERs. However, the Committee noted that it had taken these potential benefits into account when considering the cost effectiveness of ledipasvir–sofosbuvir and concluded that its recommendations for each population remained unchanged.

NHS England

4.31 The Committee discussed NHS England's submission relating to:

- the implementation of 3 oral treatments for hepatitis C in the NHS (ledipasvir–sofosbuvir, daclatasvir and ombitasvir–paritaprevir–ritonavir with or without dasabuvir)
NICE's general duties 'to have regard to the broad balance between benefits and costs of the provision of health services or of social care in England and the degree of need of persons for health services or social care in England'.

The Committee understood that NHS England considered these new oral treatments to be excellent options, but was concerned about the increase in investment and capacity needed for their implementation. The Committee heard from the patient expert that people with chronic hepatitis C appreciated the capacity constraints placed on the NHS in delivering treatment for every eligible person. The Committee recalled that treatment decisions are influenced by clinical characteristics including HCV genotype, level of liver damage, comorbidities and treatment history (see section 4.2). With these factors in mind, people with chronic hepatitis C may accept treatment being prioritised for those with highest unmet clinical need (including some people without cirrhosis), potentially determined by multidisciplinary teams.

The Committee heard from NHS England that up to 20,000 people could access treatment each year if NICE recommended these treatments for people with chronic hepatitis C (including people without cirrhosis). However, the Committee understood from the responses to the NHS England submission that this estimate was too high. The Committee heard from the clinical experts that a more realistic estimate for the number of people accessing treatment in England was likely to be between 7000 and 10,000 each year. The Committee was aware that NHS England considered that treating 7000 people with these new oral treatments each year would not be affordable within the current NHS budget. The Committee acknowledged that there would be significant impact on the total budget for specialised services associated with making these drugs available in the NHS. However, the Committee noted the responses from consultees on NHS England's submission that the estimates presented by NHS England were not robust, and that they omitted potential savings from reducing transmission of HCV. The Committee further understood that NHS England is exploring other ways of managing the financial impact of using these new drugs, such as tendering, and that it could be argued that the rebate provided by companies as part of the 2014 Pharmaceutical Price Regulation Scheme (PPRS) payment mechanism could be considered as a way of managing the budgetary impact of access to these treatments. The Committee understood, in this context, that one of the key objectives of the PPRS is to 'improve access to innovative medicines commensurate with the outcomes they offer patients by ensuring that medicines approved by NICE are available widely in the NHS'.
The Committee recognised that NICE’s guide to the methods of technology appraisal indicates that there needs to be increasing certainty of the cost effectiveness of a technology as the NHS budget impact of its adoption increases. However, the Committee noted that the ICERs were generally considerably below £20,000 per QALY gained for ledipasvir–sofosbuvir for the populations for whom it is recommended in NICE’s recommendations. The Committee emphasised that, if the uncertainties were accounted for in the modelling of the cost effectiveness (for example, incremental QALYs gained from an SVR12, the costs and benefits associated with treatment of reinfection, and savings from preventing HCV transmission), the ICERs for the recommended regimens were likely to remain substantially below £20,000 per QALY gained.

The Committee understood that, given the rapid sequential assessment of direct-acting antiviral drug combinations now licensed for treating hepatitis C, it will be worthwhile exploring whether there are combinations or sequences of treatments (for example, by genotype, treatment experience or cirrhosis status) that could be of particular value to people with chronic hepatitis C, clinicians and the NHS. The Committee agreed that further work by NICE to support this should be started as soon as possible.

The Committee discussed comments received from NHS England on the second appraisal consultation document, which proposed an ‘only in research’ recommendation for people with untreated genotype 1 HCV without cirrhosis. The Committee understood from NHS England that a clinical trial, STOP-HCV-1, will assess SVR rates in people with untreated genotype 1 HCV without cirrhosis who have direct-acting antiviral drugs, including ledipasvir–sofosbuvir, for shorter durations than stipulated in the marketing authorisation. The Committee was aware that the final protocol has not been agreed and STOP-HCV-1 has not started. It considered that the clinical effectiveness evidence available for ledipasvir–sofosbuvir for people with untreated genotype 1 HCV without cirrhosis was more robust than the evidence available for other populations considered in this technology appraisal. The Committee noted that it had recommended only the shortest duration included in the marketing authorisation for this population (8 weeks and not 12 weeks) and that the ICER was considerably below £20,000 per QALY gained. The Committee further agreed that its recommendation would not stop people from taking part in the proposed STOP-HCV-1 trial because the treatment of chronic
hepatitis C will be managed through established operational delivery networks in the NHS. The Committee concluded that an 'only in research' recommendation was not appropriate for ledipasvir–sofosbuvir in people with untreated genotype 1 HCV without cirrhosis.

Pharmaceutical Price Regulation Scheme

4.36 The Committee considered whether it should take into account the consequences of the PPRS 2014, and in particular the PPRS payment mechanism, when appraising ledipasvir–sofosbuvir. The Committee noted NICE’s position statement about this, and accepted the conclusion 'that the 2014 PPRS payment mechanism should not, as a matter of course, be regarded as a relevant consideration in its assessment of the cost effectiveness of branded medicines'. The Committee heard nothing to suggest that there is any basis for taking a different view about the relevance of the PPRS to this appraisal of ledipasvir–sofosbuvir. It therefore concluded that the PPRS payment mechanism was irrelevant in considering the cost effectiveness of ledipasvir–sofosbuvir.

Equality issues

4.37 The Committee noted the potential equality issue raised by consultees that minority ethnic groups and people with HIV co-infection are more highly represented in the genotype 4 HCV population than in the genotype 1 or 3 HCV populations. In light of NICE’s legal obligation to promote equality, the Committee considered the evidence provided by the company that included family origin by HCV genotype, and the prevalence of HIV and HCV co-infection (see section 3.56). The Committee noted that the family origin evidence was self-reported (and therefore could not be verified), and used broad categories. The Committee therefore considered this evidence to be uncertain, but acknowledged that the data had been published by Public Health England. The Committee acknowledged that the proportion of people in Europe with genotype 4 HCV was low, and the company was carrying out several studies of ledipasvir–sofosbuvir in people with genotype 4 HCV. The Committee considered the commercial-in-confidence evidence presented by the company about the genotype distribution of HCV in people with HCV and HIV co-infection and agreed that a disproportionate number of people had genotype 4 HCV and HIV co-infection compared with the overall population of
people with HCV in England. The Committee also acknowledged a comment from the Haemophilia Society that stated many people with a bleeding disorder have genotype 4 HCV because of NHS treatment. The Committee noted that no clinical evidence or cost-effectiveness analysis had been presented specifically for people with haemophilia and HCV. The Committee was satisfied that it had sufficiently considered the evidence available for people with genotype 4 HCV, which was limited. With no mature data available, the Committee had attempted to bridge this evidence gap by considering whether the evidence available for genotype 1 HCV was generalisable to the genotype 4 HCV population. The Committee was also aware of a comment made during the appraisal of \textit{daclatasvir for treating chronic hepatitis C} that genotype 3 HCV is more prevalent in people of South Asian or Pakistani family origin than other genotypes of HCV. Another consultee stated that there is evidence supporting increased rates of steatosis, hepatocellular carcinoma, cirrhosis or decompensation and death in those infected with genotype 3 HCV compared with other genotypes. The Committee understood that the consultees presented no data to support their comments. It noted that the data it had been presented with (see \textit{section 3.56}) suggested that a small proportion of people with genotype 3 HCV were of Asian family origin and from other minority ethnic groups. It also noted that the proportion of people with this protected characteristic was not disproportionately higher in genotype 3 HCV compared with other genotypes (such as genotype 4 HCV). The Committee further acknowledged that the economic analysis had accounted for different rates of disease progression for each genotype. Based on the cost-effectiveness data, it had made recommendations in line with the treatment duration and ribavirin co-administration stated in the marketing authorisation for each genotype population. Therefore, the Committee agreed that its recommendations were fair and did not constitute an equality issue.

**Summary of Appraisal Committee's key conclusions**

<table>
<thead>
<tr>
<th>TA363</th>
<th>Appraisal title: Ledipasvir–sofosbuvir for treating chronic hepatitis C</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Key conclusion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The Committee acknowledged that all the incremental cost-effectiveness ratios (ICERs) presented depended on the clinical effectiveness data, which was associated with considerable uncertainty, namely:

- the clinical study designs (open-label, non-randomised controlled evidence, with no head-to-head studies)
- the selection of sustained virological response (SVR) rates for comparators from single studies
- the use of an uncontrolled naive indirect comparison to estimate the relative effectiveness.

### Previously untreated genotype 1 hepatitis C virus (HCV) without cirrhosis

The Committee highlighted that the Evidence Review Group's (ERG's) base-case ICERs for 8 weeks and 12 weeks of ledipasvir–sofosbuvir in people with previously untreated genotype 1 HCV without cirrhosis were £9,000 (compared with peginterferon alfa plus ribavirin) and £23,000 (compared with simeprevir plus peginterferon alfa and ribavirin) per quality-adjust life year (QALY) gained respectively.

The Committee concluded that 8 weeks of ledipasvir–sofosbuvir could be considered a cost-effective use of NHS resources for people with previously untreated genotype 1 HCV without cirrhosis. The Committee concluded that 12 weeks of ledipasvir–sofosbuvir could not be considered a cost-effective use of NHS resources in this population.

### Previously untreated genotype 4 HCV without cirrhosis

The Committee agreed that it would consider the ICERs presented for people with genotype 4 HCV that used data from people with genotype 1 HCV. The Committee highlighted its conclusions for 12 weeks of ledipasvir–sofosbuvir in people with previously untreated genotype 1 HCV without cirrhosis, and concluded that it could not consider 12 weeks of ledipasvir–sofosbuvir in people with previously untreated genotype 4 HCV without cirrhosis to be a cost-effective use of NHS resources.

### Previously untreated genotype 1 or 4 HCV with cirrhosis

The Committee highlighted that the ERG's ICERs for ledipasvir–sofosbuvir in people with previously untreated genotype 1 or 4 HCV with cirrhosis were £5,000 (12 weeks of treatment, compared with no treatment) and £45,000 (24 weeks of treatment, compared with sofosbuvir plus peginterferon alfa and ribavirin) per QALY gained. On balance, the Committee concluded that only 12-week
Ledipasvir–sofosbuvir treatment could be considered a cost-effective use of NHS resources in people with previously untreated genotype 1 or 4 HCV with cirrhosis.

**Previously treated genotype 1 or 4 HCV without cirrhosis**

The Committee highlighted that the ERG’s ICERs for ledipasvir–sofosbuvir in people with previously treated genotype 1 or 4 HCV without cirrhosis were £17,000 (12 weeks of treatment, compared with no treatment) and £77,500 (24 weeks of treatment, compared with simeprevir plus peginterferon alfa and ribavirin) per QALY gained. On balance, the Committee concluded that only 12-week ledipasvir–sofosbuvir treatment could be considered a cost-effective use of NHS resources in people with previously treated genotype 1 or 4 HCV without cirrhosis.

**Previously treated genotype 1 or 4 HCV with cirrhosis**

The Committee noted that the company’s ICERs for 12 weeks’ ledipasvir–sofosbuvir in people with previously treated genotype 1 or 4 HCV with cirrhosis deemed at low risk of clinical disease progression and who have subsequent retreatment options were £4500 per QALY gained compared with no treatment when using the transition probabilities from either Fattovich et al. (1997) or Cardoso et al. (2010). The Committee concluded that 12 weeks’ ledipasvir–sofosbuvir treatment could be considered a cost-effective use of NHS resources in people with previously treated genotype 1 or 4 HCV with cirrhosis, only if all the following criteria are met:

- Child–Pugh score of 6 or below (that is, class A)
- platelet count of 75,000/mm$^3$ or more
- no features of portal hypertension (for example, absence of oesophageal varices)
- no history of an HCV-associated decompensation episode
- not previously treated with an NS5A inhibitor (for example, ledipasvir or daclatasvir).

The Committee noted that the ERG’s ICER for 24 weeks of ledipasvir–sofosbuvir in people with previously treated genotype 1 or 4 HCV with cirrhosis was £32,500 per QALY gained (compared with sofosbuvir plus peginterferon alfa and ribavirin). The Committee concluded that 24-week ledipasvir–sofosbuvir treatment could not be considered a cost-effective use of NHS resources in people with previously treated genotype 1 or 4 HCV with cirrhosis.
Genotype 3 HCV
The Committee emphasised their concerns about the robustness of the evidence base in people with genotype 3 HCV, and recognised that the uncertainties in the methods used to estimate the relative effectiveness still applied to its decision-making for people with genotype 3 HCV.

The Committee concluded that ledipasvir–sofosbuvir plus ribavirin could not be considered a cost-effective use of NHS resources in people with genotype 3 HCV.

People co-infected with HIV
The Committee acknowledged that the company's interim results suggested that the SVR12 in people with HCV and HIV co-infection was similar to that seen in people with HCV mono-infection. The Committee concluded that it was reasonable to extend the recommendations made for the mono-infected group to those co-infected with HCV and HIV.

People with advanced liver disease and after liver transplant
The Committee highlighted that the marketing authorisation for ledipasvir–sofosbuvir recommends only 24 weeks of treatment plus ribavirin in people with advanced liver disease and after liver transplant, which the company had not explored in its cost-effectiveness analysis. The Committee concluded that without cost-effectiveness estimates it was unable to make recommendations for ledipasvir–sofosbuvir plus ribavirin in people with advanced liver disease and after liver transplant.

Current practice

<table>
<thead>
<tr>
<th>Clinical need of patients, including the availability of alternative treatments</th>
<th>Treatment decisions and response to treatment are influenced by HCV genotype, level of liver damage, comorbidities and treatment history. For people with genotype 1 HCV, the Committee heard that boceprevir plus peginterferon alfa and ribavirin or telaprevir plus peginterferon alfa and ribavirin are commonly used, and that for people with genotypes 1, 3 and 4 HCV, peginterferon alfa plus ribavirin is also used in clinical practice. The Committee concluded that sofosbuvir and simeprevir, as recommended in NICE guidance, were relevant comparators.</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.2, 4.3</td>
<td></td>
</tr>
<tr>
<td><strong>Proposed benefits of the technology</strong></td>
<td>The Committee agreed that compared with current treatment, ledipasvir–sofosbuvir offers oral, shortened, and interferon-free treatment, which is particularly important to people, and a major development in the clinical management of chronic hepatitis C.</td>
</tr>
<tr>
<td><strong>How innovative is the technology in its potential to make a significant and substantial impact on health-related benefits?</strong></td>
<td></td>
</tr>
<tr>
<td><strong>What is the position of the treatment in the pathway of care for the condition?</strong></td>
<td>The Committee recognised the importance of having further treatment options available for people with chronic hepatitis C, and that an interferon-free treatment, such as ledipasvir–sofosbuvir, would provide a valuable treatment option.</td>
</tr>
<tr>
<td><strong>Adverse reactions</strong></td>
<td>The Committee acknowledged that ledipasvir–sofosbuvir offers people the option to have shortened courses of treatment, without peginterferon alfa, thereby avoiding the adverse events associated with interferon-based therapy.</td>
</tr>
<tr>
<td><strong>Evidence for clinical effectiveness</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Availability, nature and quality of evidence</strong></td>
<td>The Committee was aware that most people enrolled into the ION studies had genotype 1 HCV without cirrhosis. The Committee noted that no head-to-head studies of ledipasvir–sofosbuvir with any of the comparators listed in the scope were available, and the ION studies used historical controls. The Committee noted that there were limited data available in people with genotype 4 HCV. The Committee was aware that limited evidence was available for people with genotype 3 HCV, particularly for the previously untreated HCV population.</td>
</tr>
<tr>
<td><strong>Relevance to general clinical practice in the NHS</strong></td>
<td>The clinical experts stated that the SVR rates from the ledipasvir–sofosbuvir trials were generalisable to clinical practice. The Committee noted that the populations defined by the European Medicines Agency in the marketing authorisation for each of the treatments were open to interpretation, and heard that these groups were not clearly defined in clinical practice.</td>
</tr>
<tr>
<td><strong>Uncertainties generated by the evidence</strong></td>
<td>The Committee acknowledged the company’s view that people with genotypes 1 and 4 HCV have responded similarly to treatment in the past, and noted that the European Medicines Agency considered that the treatments for genotype 1 HCV in the ION studies were relevant to genotype 4 HCV. The Committee remained concerned about the lack of head-to-head trials, and the small numbers of people with genotype 4 HCV included in the evidence base. The Committee heard from the clinical experts that it was difficult to determine whether the SVR rates in ELECTRON-2 (genotype 3 HCV) would be seen in clinical practice, because of the small patient numbers, but emphasised that the initial 12-week results were impressive. The Committee commented that the company’s naive indirect comparison approach was not robust and leads to considerably uncertainty in determining the size of the true treatment effect. The Committee was concerned that the company had selected SVR rates from single studies without justification.</td>
</tr>
<tr>
<td><strong>Are there any clinically relevant subgroups for which there is evidence of differential effectiveness?</strong></td>
<td>Genotype 1 HCV: Sustained virological responses at 12 weeks in people with and without cirrhosis were similar, irrespective of treatment history (that is, previously untreated or previously treated HCV).</td>
</tr>
</tbody>
</table>
The company highlighted that of the 1952 people enrolled into the 3 phase III ION studies, 96.7% were cured of their HCV and only 1.8% had virological relapse after treatment. The Committee highlighted the flaws associated with studies that used historical controls rather than a conventional control group, but concluded that the 3 phase III ION studies showed that ledipasvir–sofosbuvir was an effective treatment in people with genotype 1 HCV.

The Committee concluded that it was satisfied that ledipasvir–sofosbuvir would potentially demonstrate a similar treatment effect in people with genotype 4 HCV to that shown for people with genotype 1 HCV (with or without cirrhosis).

The Committee concluded that the company's evidence for estimating the relative effectiveness of ledipasvir–sofosbuvir (with or without ribavirin) in people with genotypes 1, 3 and 4 HCV was not robust, and therefore this uncertainty should be taken into account in the decision-making.

| Evidence for cost effectiveness | 4.10 |
| Availability and nature of evidence | The Committee considered the company's economic model, the ERG's critique and the ERG's exploratory analyses. | 4.10 |
| Uncertainties around and plausibility of assumptions and inputs in the economic model | The Committee noted that the company's base-case analysis presented ICERs for a combined group of people with and without cirrhosis.  
The Committee concluded that the transition probabilities for compensated or decompensated cirrhosis to hepatocellular carcinoma may lie somewhere between the Cardoso et al. and Fattovich et al. estimates.  
The company's utility benefit for SVR was estimated with the US EQ-5D tariff, rather than the UK EQ-5D tariff. The Committee agreed that the health-related quality-of-life data available from the ION studies suggested some benefit with ledipasvir–sofosbuvir, but the results were not consistent so it was difficult to approximate how much benefit people were likely to gain. In addition, the Committee was concerned that the utility accrued over a person's lifetime was likely to be overestimated because the utility values were not adjusted for increasing age.  
The Committee commented that the ICERs were associated with some uncertainty because health effects of reinfection and HCV transmission were omitted.  
The Committee noted that retreatment was not accounted for and it was uncertain whether this was likely to increase or decrease the cost effectiveness of ledipasvir–sofosbuvir. | 4.11, 4.13–4.16 |
<p>| Incorporation of health-related quality-of-life benefits and utility values | The Committee acknowledged that none of the clinical trials collected data using the EQ-5D. The Committee noted that the company had therefore included a utility benefit of 0.04 for people who had an SVR, taken from Vera-Llonch et al. The Committee agreed that there were other benefits for people with hepatitis C (for example, the potential for regression of fibrosis) and wider benefits to society (for example, reduced transmission of HCV) that were not captured in the QALY calculation and that, if taken into account, were likely to decrease the ICERs. |
| Are there specific groups of people for whom the technology is particularly cost effective? | Please refer to the key conclusions above. |
| What are the key drivers of cost effectiveness? | The one-way sensitivity analyses showed that the company's ICERs were most sensitive to changes to the 'on-treatment' costs, discount rates of costs and effects, the SVR rates of ledipasvir–sofosbuvir and the comparators, and the transition probability from the non-cirrhotic to the compensated cirrhosis health state. The ERG concluded that using cost-effectiveness results dependent on the company's weighted-average approach (combining people with and without cirrhosis) may result in the recommendation of some options that represent an inefficient use of NHS resources. |</p>
<table>
<thead>
<tr>
<th><strong>Most likely cost-effectiveness estimate (given as an ICER)</strong></th>
<th>Please refer to the key conclusions above.</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Additional factors taken into account</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Patient access schemes</strong></td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td><strong>End-of-life considerations</strong></td>
<td>Not applicable</td>
<td></td>
</tr>
<tr>
<td><strong>Equalities considerations and social value judgements</strong></td>
<td>The Committee noted the potential equality issue raised by the company that minority ethnic groups and people with HIV co-infection are more highly represented in the genotype 4 HCV population than in the genotype 1 or 3 populations. With no mature data available for people with genotype 4 HCV, the Committee had attempted to bridge this evidence gap by considering whether the evidence available for genotype 1 HCV was generalisable to the genotype 4 HCV population. Therefore, the Committee agreed that its recommendations were fair and did not constitute an equality issue.</td>
<td>4.37</td>
</tr>
</tbody>
</table>
5 Implementation

5.1 Section 7(6) of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires clinical commissioning groups, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this appraisal within 3 months of its date of publication.

5.2 The Welsh Assembly Minister for Health and Social Services has issued directions to the NHS in Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal recommends the use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 3 months of the guidance being published.

5.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has chronic hepatitis C and the doctor responsible for their care thinks that ledipasvir–sofosbuvir is the right treatment, it should be available for use, in line with NICE's recommendations.
6 Review of guidance

6.1 All technology appraisal guidance recently developed by NICE for chronic hepatitis C will be considered for incorporation and contextualisation in the NICE guideline on hepatitis C.

Andrew Dillon
Chief Executive
November 2015
7  Appraisal Committee members, guideline representatives and NICE project team

Appraisal Committee members

The Appraisal Committees are standing advisory committees of NICE. Members are appointed for a 3-year term. A list of the Committee members who took part in the discussions for this appraisal appears below. There are 4 Appraisal Committees, each with a chair and vice chair. Each Appraisal Committee meets once a month, except in December when there are no meetings. Each Committee considers its own list of technologies, and ongoing topics are not moved between Committees.

Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal.

The minutes of each Appraisal Committee meeting, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.

Professor Gary McVeigh (Chair)
Professor of Cardiovascular Medicine, Queen's University Belfast and Consultant Physician, Belfast City Hospital

Dr Lindsay Smith (Vice Chair)
GP, West Coker Surgery, Somerset

Dr Aomesh Bhatt
Regulatory and Medical Affairs Director Europe and North America, Reckitt Benckiser

Dr Andrew Black
GP, Mortimer Medical Practice, Herefordshire

Professor David Bowen
Consultant Haematologist, Leeds Teaching Hospitals NHS Trust

Dr Matthew Bradley
Therapy Area Leader, Global Health Outcomes, GlaxoSmithKline
Dr Ian Campbell  
Honorary Consultant Physician, Llandough Hospital, Cardiff

Dr Ian Davidson  
Lecturer in Rehabilitation, University of Manchester

Professor Simon Dixon  
Professor of Health Economics, University of Sheffield

Mrs Susan Dutton  
Senior Medical Statistician, Oxford Clinical Trials Research Unit

Dr Alexander Dyker  
Consultant Physician, Wolfson Unit of Clinical Pharmacology, University of Newcastle

Mrs Gillian Ells  
Prescribing Advisor – Commissioning, NHS Hastings and Rother and NHS East Sussex Downs and Weald

Professor Paula Ghaneh  
Professor and Honorary Consultant Surgeon, University of Liverpool

Dr Susan Griffin  
Research Fellow, Centre for Health Economics, University of York

Professor Carol Haigh  
Professor of Nursing, Manchester Metropolitan University

Professor John Henderson  
Professor of Paediatric Respiratory Medicine, University of Bristol and Bristol Royal Hospital for Children

Professor John Hutton  
Professor of Health Economics, University of York

Professor Steven Julious  
Professor in Medical Statistics, University of Sheffield
Dr Tim Kinnaird
Lead Interventional Cardiologist, University Hospital of Wales, Cardiff

Dr Warren Linley
Independent Pharmacist and Health Economist

Dr Malcolm Oswald
Lay Member

Professor Femi Oyebode
Professor of Psychiatry and Consultant Psychiatrist, The National Centre for Mental Health

Dr Mohit Sharma
Consultant in Public Health, Public Health England

Dr Murray Smith
Associate Professor in Social Research in Medicines and Health, University of Nottingham

Guideline representatives

The following individuals, representing the Guideline Committee responsible for developing NICE’s guideline related to this topic, were invited to attend the meeting to observe and to contribute as advisers to the Committee.

Professor Matthew Hickman
Professor of Public Health and Epidemiology, University of Bristol

NICE project team

Each technology appraisal is assigned to a team consisting of 1 or more health technology analysts (who act as technical leads for the appraisal), a technical adviser and a project manager.

Martyn Burke
Technical Lead

Melinda Goodall and Nwamaka Umeweni
Technical Advisers
8 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by School of Health and Related Research (ScHARR), The University of Sheffield:


B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

- Gilead Sciences

II. Professional/expert and patient/carer groups:

- Haemophilia Society
- Hepatitis C Trust
- HIV i-Base
- Liver4Life
- Positively UK
- British Association for the Study of the Liver
- British HIV Association
- British Society of Gastroenterology
- Royal College of Pathologists
III. Other consultees:

- Department of Health
- NHS England
- Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Janssen (simeprevir, telaprevir)
- Merck Sharp & Dohme (boceprevir, peginterferon alfa 2b, ribavirin)
- Roche Products (peginterferon alfa 2a, ribavirin)
- Foundation for Liver Research
- School of Health and Related Research (ScHARR)
- National Institute for Health Research Health Technology Assessment Programme
- Public Health England

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on ledipasvir–sofosbuvir by attending the initial Committee discussion and providing a written statement to the Committee or attending subsequent Committee discussions. They were also invited to comment on the ACD.

- Professor Matthew Cramp, Consultant Hepatologist, nominated by Gilead Sciences – clinical expert
- Professor Geoff Dusheiko, Emeritus Professor of Medicine, nominated by Bristol–Myers Squibb – clinical expert
- Dr Helen Harris, Clinical Scientist and Research Associate, nominated by Public Health England – clinical expert

- Dr Ranjababu Kulasegaram, Consultant Physician, nominated by the British HIV Association and British Association for Sexual Health and HIV – clinical expert

- Dr Charles Millson, Consultant Hepatologist, nominated by the British Society of Gastroenterology – clinical expert

- Dr Terence Wong, Consultant Gastroenterologist and Hepatologist, nominated by the British Society of Gastroenterology – clinical expert

- Mr Charles Gore, Chief Executive of the Hepatitis C Trust, nominated by the Hepatitis C Trust – patient expert

- Mr Richard Hall, Co-Founder of Liver4Life, nominated by Liver4Life – patient expert

- Mr Robert James, nominated by the British HIV Association and British Association for Sexual Health and HIV – patient expert

- Ms Raquel Peck, nominated by the Hepatitis C Trust – patient expert

D. The following individuals were nominated as NHS commissioning experts by NHS England. They gave their expert/NHS commissioning personal view on ledipasvir–sofosbuvir for treating chronic hepatitis C by attending the Committee discussion. They were also invited to comment on the ACD.

- James Palmer, Clinical Director, Specialised Commissioning selected by NHS England – NHS commissioning expert

- Malcolm Qualie, Pharmacy Lead, Specialised Services selected by NHS England – NHS commissioning expert

E. Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

- Gilead Sciences
About this guidance

NICE technology appraisal guidance is about the use of new and existing medicines and treatments in the NHS.

This guidance was developed using the NICE single technology appraisal process.

We have produced information for the public explaining this guidance. Information about the evidence the guidance is based on is also available.

NICE produces guidance, standards and information on commissioning and providing high-quality healthcare, social care, and public health services. We have agreements to provide certain NICE services to Wales, Scotland and Northern Ireland. Decisions on how NICE guidance and other products apply in those countries are made by ministers in the Welsh government, Scottish government, and Northern Ireland Executive. NICE guidance or other products may include references to organisations or people responsible for commissioning or providing care that may be relevant only to England.

Your responsibility

This guidance represents the views of NICE and was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Copyright

© National Institute for Health and Care Excellence 2015. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.
Accreditation

NICE accredited

www.nice.org.uk/accreditation